60850

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Hong Liu Examiner # : _____ Date: 2/21/02

Art Unit: 1624 Phone Number 30 6-5814 Serial Number: 09/719,457

Mail Box and Bldg/Room Location: 4E01 Results Format Preferred (circle): PAPER DISK E-MAIL

If mor than ne search is submitted, please prioritiz searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Barb please!



R^5 is alkyl, alkyl-$C(=O)$-O-Z^5,

(C_0-C_6)alkyl-$C(=O)$-NH-$(CH_2)_m$-Z^3

or aryl.

See provisos p. 324

Point of Contact:
Barb O'Bryen
Technical Information Specialist
STIC CM1 6A05 308-4291

****

STAFF USE ONLY

Searcher: BOB

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: 2-25-02

Date Completed: 2-27-02

Searcher Prep & Review Time: 160

Clerical Prep Time: _____

Online Time: 134

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) 7

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

STN 582

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____

PTO-1590 (8-01)

```
=> fil reg; d stat que l20; d stat que l27; fil capl; d que nos 128
FILE 'REGISTRY' ENTERED AT 15:28:39 ON 27 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   25 FEB 2002  HIGHEST RN 395638-68-3
DICTIONARY FILE UPDATES:  25 FEB 2002  HIGHEST RN 395638-68-3

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between
12/27/01 and 1/23/02.  Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved.  Also, note that searches
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files
incorporating CAS Registry Numbers with the P indicator between 12/27/01
and 1/23/02, are encouraged to re-run these strategies.  Contact the
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,
worldwide, or send an e-mail to help@cas.org for further assistance or to
receive a credit for any duplicate searches.

L1                  STR
```



= ring or chain bonds & nodes

full file search done on this structure

```
VAR G1=NH/O
REP G2=(0-6) CH2
REP G3=(0-5) CH2
```

VAR G5=9/COOH/11/15/19/22/27/34/36/CB
VAR G6=H/9
NODE ATTRIBUTES:
NSPEC IS RC AT 40
NSPEC IS RC AT 41
CONNECT IS E1 RC AT 9
CONNECT IS E1 RC AT 13
CONNECT IS E1 RC AT 26
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L2 (332465)SEA FILE=REGISTRY ABB=ON (16.195.22 OR 16.195.24 OR 333.871)/R
ID
L3 4066 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L9 STR



subset search done looking for this structure

```
REP G3=(0-5) CH2
VAR G6=H/9
VAR G7=50/51/54
VAR G8=55/56/59/62/65/69/73/75/77/80/83/85/89/94/97
VAR G10=O/S/110/108-90 109-92/112-90 114-92
VAR G11=9/NH2/102/105/115/117
VAR G12=O/S/110/108-98 109-100/112-98 114-100
NODE ATTRIBUTES:
NSPEC   IS RC     AT   7
CONNECT IS E1  RC AT   9
CONNECT IS E1  RC AT  50
CONNECT IS E2  RC AT  55
CONNECT IS E3  RC AT  56
CONNECT IS E3  RC AT  59
CONNECT IS E3  RC AT  62
CONNECT IS E3  RC AT  65
CONNECT IS E3  RC AT  69
CONNECT IS E3  RC AT  73
CONNECT IS E1  RC AT  74
CONNECT IS E3  RC AT  75
CONNECT IS E3  RC AT  77
CONNECT IS E1  RC AT  79
CONNECT IS E3  RC AT  80
CONNECT IS E1  RC AT  82
CONNECT IS E3  RC AT  83
CONNECT IS E3  RC AT  85
CONNECT IS E3  RC AT  89
CONNECT IS E3  RC AT  94
CONNECT IS E3  RC AT  97
CONNECT IS E1  RC AT 103
CONNECT IS E1  RC AT 104
CONNECT IS E1  RC AT 106
CONNECT IS E1  RC AT 116
CONNECT IS E1  RC AT 120
CONNECT IS E1  RC AT 121
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  53
GGCAT   IS UNS  AT  54
GGCAT   IS UNS  AT 115
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X12 C  AT  50

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  88

STEREO ATTRIBUTES: NONE
L20             25 SEA FILE=REGISTRY SUB=L3 SSS FUL L9

100.0% PROCESSED    542 ITERATIONS                  25 ANSWERS
SEARCH TIME: 00.00.08


L1              STR
```





same full file search as before

VAR G1=NH/O
REP G2=(0-6) CH2
REP G3=(0-5) CH2
VAR G5=9/COOH/11/15/19/22/27/34/36/CB
VAR G6=H/9
NODE ATTRIBUTES:
NSPEC IS RC AT 40
NSPEC IS RC AT 41
CONNECT IS E1 RC AT 9
CONNECT IS E1 RC AT 13
CONNECT IS E1 RC AT 26
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L2 (332465)SEA FILE=REGISTRY ABB=ON (16.195.22 OR 16.195.24 OR 333.871)/R
ID
L3 4066 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L14 STR







subset search done looking for intersection of this structure & structure on next page

VAR G1=H/10/13/19/20/21/24/26/31/35
REP G5=(0-6) CH2
REP G6=(0-5) CH2
VAR G9=19/20
VAR G10=N/HY
VAR G12=H/20
NODE ATTRIBUTES:
NSPEC IS RC AT 80
CONNECT IS E1 RC AT 20
CONNECT IS E2 RC AT 35
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L16 STR









VAR G2=NH2/41/43/47
VAR G3=CH2/64/67/70/75
VAR G4=50/CH2/O/S/NH/52/53/SO2
REP G5=(0-6) CH2
REP G6=(0-5) CH2
VAR G7=O/S/58/56-71 57-73/60-71 62-73
VAR G8=O/S/58/56-76 57-78/60-76 62-78
VAR G10=N/HY
REP G11=(1-11) CH2
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 42
CONNECT IS E1 RC AT 46
CONNECT IS E1 RC AT 52
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 52
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE
L27 1828 SEA FILE=REGISTRY SUB=L3 SSS FUL (L14 AND L16)

100.0% PROCESSED 2492 ITERATIONS 1828 ANSWERS
SEARCH TIME: 00.00.06

FILE 'CAPLUS' ENTERED AT 15:28:40 ON 27 FEB 2002

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Feb 2002 VOL 136 ISS 9
FILE LAST UPDATED: 26 Feb 2002 (20020226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

```
L1              STR
L2  (    332465)SEA FILE=REGISTRY ABB=ON  (16.195.22 OR 16.195.24 OR 333.871)/R
                ID
L3         4066 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L9              STR
L14             STR
L16             STR
L20          25 SEA FILE=REGISTRY SUB=L3 SSS FUL L9
L27        1828 SEA FILE=REGISTRY SUB=L3 SSS FUL (L14 AND L16)
L28          43 SEA FILE=CAPLUS ABB=ON  L20 OR L27
```

```
=> d que l25
L22          46 SEA FILE=CAPLUS ABB=ON  THURIEAU C?/AU
L23         809 SEA FILE=CAPLUS ABB=ON  IMIDAZOLYL/TI
L24           3 SEA FILE=CAPLUS ABB=ON  L22 AND L23
L25           2 SEA FILE=CAPLUS ABB=ON  DERIVATIVES/TI AND L24
```

3 inventors

```
=> s l28 not l25
L34          41 L28 NOT L25
```

removed inventors' own work from answer set because they had many, many compounds (& inventors' citations printed at end)

```
=> fil uspatf; d que nos l29
FILE 'USPATFULL' ENTERED AT 15:29:25 ON 27 FEB 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 26 Feb 2002 (20020226/PD)
FILE LAST UPDATED: 26 Feb 2002 (20020226/ED)
HIGHEST GRANTED PATENT NUMBER: US6351850
HIGHEST APPLICATION PUBLICATION NUMBER: US2002023282
CA INDEXING IS CURRENT THROUGH 26 Feb 2002 (20020226/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 26 Feb 2002 (20020226/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2001
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2001
```

```
>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or        <<<
>>>  applications.  USPAT2 contains full text of the latest US        <<<
>>>  publications, starting in 2001, for the inventions covered in    <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original    <<<
>>>  published document but also a list of any subsequent             <<<
>>>  publications.  The publication number, patent kind code, and     <<<
>>>  publication date for all the US publications for an invention    <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL  <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                        <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together       <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to         <<<
>>>  enter this cluster.                                              <<<
>>>                                                                   <<<
>>>  Use USPATALL when searching terms such as patent assignees,      <<<
>>>  classifications, or claims, that may potentially change from    <<<
>>>  the earliest to the latest publication.                          <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L1                STR
L2   (     332465)SEA FILE=REGISTRY ABB=ON  (16.195.22 OR 16.195.24 OR 333.871)/R
                  ID
L3           4066 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L9                STR
L14               STR
L16               STR
L20            25 SEA FILE=REGISTRY SUB=L3 SSS FUL L9
L27          1828 SEA FILE=REGISTRY SUB=L3 SSS FUL (L14 AND L16)
L29            11 SEA FILE=USPATFULL ABB=ON  L20 OR L27


=> dup rem l29,l34
FILE 'USPATFULL' ENTERED AT 15:29:30 ON 27 FEB 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 15:29:30 ON 27 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L34
L35            49 DUP REM L29 L34 (3 DUPLICATES REMOVED)
                  ANSWERS '1-11' FROM FILE USPATFULL
                  ANSWERS '12-49' FROM FILE CAPLUS

=> d ibib abs hitstr l35 1-49; fil cao; d que nos l32

L35  ANSWER 1 OF 49  USPATFULL                          DUPLICATE 1
ACCESSION NUMBER:       2002:1332  USPATFULL
TITLE:                  Derivatives of 2-(iminomethyl)amino-phenyl, their
                        preparation, their use as medicaments and the
                        pharmaceutical compositions containing them
INVENTOR(S):            Chabrier de Lassauniere, Pierre Etienne, Paris, FRANCE
                        Auvin, Serge, Mauchamps, FRANCE
                        Bigg, Dennis, Gif-sur-Yvette, FRANCE
                        Auguet, Michel, Palaiseau, FRANCE
                        Harnett, Jeremiah, Gif-sur-Yvette, FRANCE
PATENT ASSIGNEE(S):     Societe de Conseils de Recherches et d'Applications
```

Scientifiques (S.C.R.A.S.), FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335445	B1	20020101
APPLICATION INFO.:	US 1999-456205		19991207 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 381749		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-3528	19970324
	FR 1997-7701	19970620

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Patel, Sudhaker B.
LEGAL REPRESENTATIVE: Bierman, Muserlian and Lucas
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound selected from the group consisting of a compound of the formula ##STR1##

wherein A is selected from the group consisting of ##STR2##

and the other substituents are defined in the specification having an inhibitory activity of NO-synthase enzymes producing nitrogen mono-oxide and/or an activity which traps the reactive oxygen species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **218944-42-4P 384833-39-0P**
(prepn. of N-phenylthiophenecarboxamidines and analogs as NO synthase and lipid peroxidn. inhibitors)

RN 218944-42-4 USPATFULL

CN Benzamide, N-[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[(imino-2-thienylmethyl)amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 384833-39-0 USPATFULL

CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[(imino-2-thienylmethyl)amino]-N-methyl- (9CI) (CA INDEX NAME)



IT **218944-36-6P 218944-40-2P 218944-41-3P**
(prepn. of N-phenylthiophenecarboxamidines and analogs as NO synthase and lipid peroxidn. inhibitors)
RN 218944-36-6 USPATFULL
CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 218944-40-2 USPATFULL
CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 218944-41-3 USPATFULL
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 2 OF 49 USPATFULL DUPLICATE 2
ACCESSION NUMBER: 95:36525 USPATFULL
TITLE: Symmetrical and unsymmetrical polyalkylamine metal complexes for ligand extraction and generation

INVENTOR(S): Smith, Kevin M., Davis, CA, United States
Ciccone, Joseph P., Davis, CA, United States
Ramana, N. Venkata, Burnaby, Canada
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5410052		19950425
APPLICATION INFO.:	US 1990-587973		19900925 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-558516, filed on 31 Jul 1989, now abandoned which is a division of Ser. No. US 1989-306730, filed on 3 Feb 1989, now patented, Pat. No. US 4959135 which is a continuation-in-part of Ser. No. US 1987-18891, filed on 25 Feb 1987, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Nazario, Porfirio
LEGAL REPRESENTATIVE: Phillips Moore Lempio & Finley
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,9,13
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2560
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mthods and apparatus for the extraction of a ligand such as molecular oxygen from a first fluid environment and for release of a ligand such as molecular oxygen, as well as ligand carrier compounds therefore comprising linear, pentadentate polyalkylamines and transition metal ions. The carrier compounds have the general formula: ##STR1## where, each of R.sub.1 and R.sub.2 is independently an organic group including a sulfur, an oxygen or a nitrogen coordinated to M;

each of m, n. o, and p is 1, 2 3, or 4;

X is selected from the group consisting of 2,6-pyridyl, 2,6-piperidyl, 2,5pyrrolyl, 2,4-imidazolyl, substituted heterocyclic amines, --O--, --S-- >P--R.sub.3, and >N--R.sub.3 where R.sub.3 is hydrogen, lower alkyl, or aralkyl; and

M is a transition metal ion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **167269-16-1P 167269-17-2P 167269-18-3P 167269-19-4P 167269-20-7P 167269-25-2P 167269-26-3P 167269-27-4P 167269-28-5P 167269-29-6P**
(prepn. of polyalkylamines and cobalt polyalkylamine complexes as oxygen carriers)
RN 167269-16-1 USPATFULL
CN Methanediamine, N-[[[(4-methyl-1H-imidazol-2-yl)methyl]amino]methyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 167269-17-2 USPATFULL

CN 1,2-Ethanediamine, N-[2-[[(4-methyl-1H-imidazol-2-yl)methyl]amino]ethyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 167269-18-3 USPATFULL
CN 1,3-Propanediamine, N-[3-[[(4-methyl-1H-imidazol-2-yl)methyl]amino]propyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 167269-19-4 USPATFULL
CN 1,4-Butanediamine, N-[4-[[(4-methyl-1H-imidazol-2-yl)methyl]amino]butyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 167269-20-7 USPATFULL
CN 1,5-Pentanediamine, N-[5-[[(4-methyl-1H-imidazol-2-yl)methyl]amino]pentyl]-N'-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 167269-25-2 USPATFULL
CN Methanediamine, N-[[[[4-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]amino]methyl]-N'-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 167269-26-3 USPATFULL
CN 1,2-Ethanediamine, N-[2-[[[4-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]amino]ethyl]-N'-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 167269-27-4 USPATFULL
CN 1,3-Propanediamine, N-[3-[[[4-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]amino]propyl]-N'-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 167269-28-5 USPATFULL
CN 1,4-Butanediamine, N-[4-[[[4-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]amino]butyl]-N'-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 167269-29-6 USPATFULL
CN 1,5-Pentanediamine, N-[5-[[[4-methyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]amino]pentyl]-N'-[(3-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 3 OF 49 USPATFULL DUPLICATE 3
ACCESSION NUMBER: 91:94552 USPATFULL
TITLE: 2-aryl-3-heterocyclicmethyl-3H-imidazo[4,5-b]pyridines as anxiolytics and anticonvulsants
INVENTOR(S): Taylor, Jr., Chandler R., Mechanicsville, VA, United States
Moses, Meredith, Glen Allen, VA, United States
PATENT ASSIGNEE(S): A. H. Robins Company, Incorporated, Richmond, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5066654		19911119
APPLICATION INFO.:	US 1990-601967		19901022 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Jackson, Richard K.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 514
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are disclosed compounds of the formula ##STR1## wherein Ar is ##STR2## Het is ##STR3## R.sup.1, R.sup.2, and R.sup.3 are each, independently, hydrogen, alkyl, aralkyl, alkoxy, carbalkoxy, trifluoromethyl, halo, cyano, or nitro;

R.sup.4 is hydrogen, alkyl, aralkyl, alkoxy, carbalkoxy, halo, or trifluoromethyl;

Y is NH, O, or S;

X is CH, or N;

or a pharmaceutically acceptable salt thereof, which, by virtue of their ability to bind to the benzodiazepine receptor, and prevent electrically or chemically induced seizures are useful as anxiolytic and anticonvulsant agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **138799-96-9**
(reaction of, in prepn. of anticonvulsants and anxiolytics)
RN 138799-96-9 USPATFULL
CN 1H-Imidazole-2-methanamine, 4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L35 ANSWER 4 OF 49 USPATFULL
ACCESSION NUMBER: 2002:22483 USPATFULL
TITLE: FARNESYL TRANSFERASE INHIBITORS
INVENTOR(S): GORDON, THOMAS D., MEDWAY, MA, UNITED STATES
MORGAN, BARRY A., FRANKLIN, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013319	A1	20020131
APPLICATION INFO.:	US 1996-752546	A1	19961120 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-602438, filed on 16 Feb 1996, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Brian R Morrill, Biomeasure Incorporated, 27 Maple Street, Milford, MA, 01757-3650
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 1544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A family of compounds capable of inhibiting the activity of farnesyl transferase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **195449-70-8P**
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)
RN 195449-70-8 USPATFULL
CN Propanamide, 2-amino-3-mercapto-N-[1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **195449-56-0P 195449-72-0P**
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)
RN 195449-56-0 USPATFULL
CN Propanamide, 2-amino-3-mercapto-N-methyl-N-[1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195449-72-0 USPATFULL
CN Propanamide, 3,3'-dithiobis[2-amino-N-[1-[5-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [1S-[1R*[S*[S*(R*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **195450-28-3P 195450-42-1P 195450-43-2P**
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)
RN 195450-28-3 USPATFULL
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-42-1 USPATFULL

CN 1H-Imidazole-2-methanamine, .alpha.-butyl-N-methyl-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-43-2 USPATFULL
CN Carbamic acid, [2-[methyl[1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]-2-oxo-1-[[(triphenylmethyl)thio]methyl]ethyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 5 OF 49 USPATFULL

ACCESSION NUMBER:	1999:137250 USPATFULL
TITLE:	Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
INVENTOR(S):	Ali, Fadia El-Fehail, Cherry Hill, NJ, United States Bondinell, William, Wayne, PA, United States Huffman, William Francis, Malvern, PA, United States Lago, M. Amparo, Audubon, PA, United States Keenan, Richard McCulloch, Malvern, PA, United States Kwon, Chet, King of Prussia, PA, United States Miller, William Henry, Schwenksville, PA, United States Nguyen, Thomas, King of Prussia, PA, United States Takata, Dennis T., Flourtown, PA, United States
PATENT ASSIGNEE(S):	SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5977101		19991102	
	WO 9600730		19960111	
APPLICATION INFO.:	US 1996-505171		19961220	(8)
	WO 1995-US8306		19950629	
			19961220	PCT 371 date
			19961220	PCT 102(e) date

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gupta, Yogendra N.
LEGAL REPRESENTATIVE:	McCarthy, Mary E., Venetianer, Stephen, Kinzig, Charles M.
NUMBER OF CLAIMS:	18

EXEMPLARY CLAIM: 1
LINE COUNT: 5856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **175529-80-3P**
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)
RN 175529-80-3 USPATFULL
CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT **175531-38-1**
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)
RN 175531-38-1 USPATFULL
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



IT **175531-07-4P**
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)
RN 175531-07-4 USPATFULL
CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 6 OF 49 USPATFULL
ACCESSION NUMBER: 97:83962 USPATFULL
TITLE: Trisubstituted benzene derivatives, composition and methods of treatment
INVENTOR(S): Kimura, Teiji, Ibaraki, Japan
Watanabe, Nobuhisa, Ibaraki, Japan
Takase, Yasutaka, Ibaraki, Japan
Hayashi, Kenji, Ibaraki, Japan
Matsui, Makoto, Ibaraki, Japan
Ikuta, Hironori, Ibaraki, Japan
Yamagishi, Youji, Ibaraki, Japan
Akasaka, Kozo, Ibaraki, Japan
Tanaka, Hiroshi, Ibaraki, Japan
Ohtsuka, Issei, Ibaraki, Japan
Saeki, Takao, Ibaraki, Japan
Kogushi, Motoji, Ibaraki, Japan
Fujimori, Tohru, Tenafly, NJ, United States
Saito, Isao, Ibaraki, Japan
PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668136		19970916
APPLICATION INFO.:	US 1991-757908		19910911 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-251897	19900925
	JP 1991-91477	19910329

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gupta, Yogendra N.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 3302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A benzene, pyridine or pyrimidine derivative having the below shown formula is novel and useful as an anti-arteriosclerotic agent. ##STR1## wherein R.sup.1 stands for a lower alkyl group, an amino group which may be substituted, or the like; R.sup.2 stands for a group represented by the formula: ##STR2## (wherein R.sup.16 stands for an alkyl group having 1 to 6 carbon atoms, or the like) or the like; R.sup.3 stands for a group represented by the formula: --O--(CH.sub.2).sub.m --Y (Y stands for an imidazolyl or piperazinyl group, or the like and m is 1 to 6) or the like; R.sup.5 stands for a hydrogen atom, a lower alkyl group, or the like; A stands for a group represented by the formula: ##STR3## (wherein R.sup.6 stands for a hydrogen atom, a lower alkyl group, or the like), --N.dbd., or the like; and B stands for a group represented by the formula: ##STR4## (wherein R.sup.4 stands for a hydrogen or the like), --N.dbd., or the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **141799-93-1P**
(prepn. of)
RN 141799-93-1 USPATFULL
CN Urea, N-[2-methyl-6-[3-[5-methyl-2-[(pentylamino)methyl]-4-phenyl-1H-imidazol-1-yl]propoxy]phenyl]-N'-pentyl- (9CI) (CA INDEX NAME)



L35 ANSWER 7 OF 49 USPATFULL

ACCESSION NUMBER:	93:14582 USPATFULL
TITLE:	Thione dopamine beta hydroxylase inhibitors
INVENTOR(S):	Matthews, Donald P., West Chester, OH, United States McCarthy, James R., West Chester, OH, United States Whitten, Jeffrey P., Cincinnati, OH, United States Broersma, Jr., Robert J., Noblesville, IN, United States
PATENT ASSIGNEE(S):	Merrell Dow Pharmaceuticals Inc., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5189052		19930223
APPLICATION INFO.:	US 1989-453648		19891220 (7)
DISCLAIMER DATE:	20081015		

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1987-114168, filed on 27 Oct 1987, now patented, Pat. No. US 5057613 which is a continuation-in-part of Ser. No. US 1986-860263, filed on 6 May 1986, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Kolano, John J.
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
LINE COUNT:	409

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Imidazole-2-thione derivatives useful as antihypertensive agents are described herein. The compounds are obtained by cyclization of an appropriate open-chain compound such as an appropriately substituted thiourea.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **113825-18-6P**
(prepn. and cyclocondensation of, with thiocyanate)

RN 113825-18-6 USPATFULL

CN 1H-Imidazole-2-methanamine, N-(2,2-diethoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 8 OF 49 USPATFULL
ACCESSION NUMBER: 91:84556 USPATFULL
TITLE: Novel thione dopamine beta hydroxylase inhibitors
INVENTOR(S): Matthews, Donald P., West Chester, OH, United States
McCarthy, James R., West Chester, OH, United States
Whitten, Jeffrey P., Zionsville, IN, United States
Broersma, Jr., Robert J., Noblesville, IN, United States
PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5057613		19911015
APPLICATION INFO.:	US 1987-114168		19871027 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-860263, filed on 6 May 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Kolano, John J.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Imidazole-2-thione derivatives useful as antihypertensive agents are described herein. The compounds are obtained by cyclization of an appropriate open-chain compound such as an appropriately substituted thiourea.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **113825-18-6P**
(prepn. and cyclocondensation of, with thiocyanate)
RN 113825-18-6 USPATFULL
CN 1H-Imidazole-2-methanamine, N-(2,2-diethoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 9 OF 49 USPATFULL
ACCESSION NUMBER: 89:17401 USPATFULL
TITLE: Novel imidazole dopamine beta hydroxylase inhibitors
INVENTOR(S): Matthews, Donald P., West Chester, OH, United States
McCarthy, James R., West Chester, OH, United States
Whitten, Jeffrey P., Zionsville, IN, United States
Broersma, Jr., Robert J., Noblesville, IN, United States

PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals Inc., Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4810800		19890307
APPLICATION INFO.:	US 1988-188661		19880429 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-114166, filed on 27 Oct 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-860263, filed on 6 May 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Kolano, John J.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,2-Disubstituted imidazoles useful as antihypertensive agents are described herein. The compounds are obtained from the appropriate 1-substituted imidazole which can be reacted with methyl oxalyl chloride to give the oxalyl derivative or it can be reacted with cyanogen chloride to give the 2-carbonitrile which can then be converted to the other derivatives desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **113825-18-6P**
(prepn. and cyclocondensation of, with thiocyanate)
RN 113825-18-6 USPATFULL
CN 1H-Imidazole-2-methanamine, N-(2,2-diethoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 10 OF 49 USPATFULL
ACCESSION NUMBER: 75:68889 USPATFULL
TITLE: 2-Aminoalkyl-1-(pyridylcarbonylphenyl)imidazole compounds
INVENTOR(S): Nakanishi, Michio, Oita, Japan
Yokobe, Tetsuo, Fukuoka, Japan
Arai, Tomio, Fukuoka, Japan
Abe, Masao, Fukuoka, Japan
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3927011		19751216
APPLICATION INFO.:	US 1974-432115		19740109 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1973-52232	19730510
	JP 1973-53826	19730514
	JP 1973-68116	19730616

JP 1973-76945 19730707
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Randolph, John D.
LEGAL REPRESENTATIVE: Sughrue, Rothwell, Mion, Zinn & Macpeak
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Aminoalkyl-1-(pyridylcarbonylphenyl)imidazole compounds of the formula: ##SPC1##

And pharmaceutically acceptable acid addition salts thereof, wherein

X is H, nitro or halogen,

Alk is methylene (--CH.sub.2 --) or ethylene (--CH.sub.2 .sub.2 --), and

Am is dialkylamino, N-alkyl-N-aralkyl-amino, 1-pyrrolidinyl, piperidino, morpholino or 4-methyl-1-piperazinyl, in which definitions the term "alkyl" means that the alkyl group has no more than 4 carbon atoms, and the aralkyl group is selected from the group consisting of benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, phenethyl and dimethoxyphenethyl,

And pharmaceutical compositions containing the same, and methods of treating cerebral dysfunction in mammals therewith are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **54534-29-1P**
(prepn. of)
RN 54534-29-1 USPATFULL
CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 11 OF 49 USPATFULL
ACCESSION NUMBER: 75:57808 USPATFULL
TITLE: 1-[2-(2-Chlorobenzoyl)-4-nitrophenyl]-2-(diethylaminomethyl)-imidazole
INVENTOR(S): Nakanishi, Michio, Oita, Japan
Yokobe, Tetsuo, Fukuoka, Japan
Arai, Tomio, Fukuoka, Japan
Abe, Masao, Fukuoka, Japan
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3915981		19751028

APPLICATION INFO.: US 1974-431993 19740109 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1973-31153	19730316
	JP 1973-32157	19730320

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Winters, Sherman D.
LEGAL REPRESENTATIVE: Sughrue, Rothwell, Mion, Zinn & Macpeak
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 1-[2-(2-Chlorobenzoyl)-4-nitrophenyl]-2-(diethylaminomethyl)imidazole of the formula: ##SPC1##

And pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions containing the same, and methods of treating cerebral dysfunction in mammals therewith are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **54534-29-1P**
(prepn. of)
RN 54534-29-1 USPATFULL
CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)



L85 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:581850 CAPLUS
DOCUMENT NUMBER: 135:152807
TITLE: Preparation of substituted imidazoles as selective modulators of bradykinin B2 receptors
INVENTOR(S): Rachwal, Stanislaw; Hutchison, Alan; Shaw, Kenneth; Maynard, George D.; He, Xiao-Shu; Desimone, Robert; Hodgetts, Kevin J.
PATENT ASSIGNEE(S): Nuerogen Corporation, USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056995	A1	20010809	WO 2001-US1618	20010117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-176869 P 20000118
OTHER SOURCE(S): MARPAT 135:152807

GI



I

AB The title compds. [I; R1 = (un)substituted aralkyl, heteroarylalkyl, allyl; R2, r3 = halo, CF3, alkoxy, etc.; R2 and R3 may be taken together to form a carbocyclic or heterocyclic satd. ring; R4 = alkyl; R5 = halo, CF3; R6-R8 = H, CF3, CN, etc.; Y = a bond, CH2] which are modulators of bradykinin B2 receptors, were prepd. E.g., a multi-step synthesis of I [R1 = 2-ClC6H4CH2; R2, R3 = Me; R4 = 3-methylbutyl; R5 = Cl; R6 = 3-OMe; R7 = 4-OMe; R8 = H; Y = a bond] was given. The compds. I are useful in the diagnosis and treatment of renal diseases, heart failure, hypertension, Meniere's disease, vaginal inflammation and pain, peripheral circulatory disorders, climacteric disturbance, retinochoroidal circulatory disorders, myocardial ischemia, myocardial infarction, postmyocardial infarction syndrome, angina pectoris, restenosis after percutaneous transluminal coronary angioplasty, hepatitis, liver cirrhosis, pancreatitis, ileus, diabetes, diabetic complications, male infertility, glaucoma, pain, asthma, and rhinitis, and for the increase of permeability of the blood-brain barrier or the blood-brain-tumor barrier.

IT **352437-16-2P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted imidazoles as selective modulators of bradykinin B2 receptors)

RN 352437-16-2 CAPLUS

CN Benzamide, 2-chloro-N-[[1-[(2-cyanophenyl)methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



IT **352437-13-9P 352437-14-0P 352437-15-1P**
352437-17-3P 352437-18-4P 352437-19-5P
352437-20-8P 352437-21-9P 352437-25-3P
352437-26-4P 352437-27-5P 352437-28-6P
352437-29-7P 352437-31-1P 352437-33-3P
352437-35-5P 352437-42-4P 352437-43-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted imidazoles as selective modulators of bradykinin B2 receptors)

RN 352437-13-9 CAPLUS

CN Benzamide, 2-chloro-N-[[1-[(2-chlorophenyl)methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-14-0 CAPLUS

CN Benzamide, 2-chloro-3,4-dimethoxy-N-[[1-[(2-methoxyphenyl)methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-15-1 CAPLUS
CN Acetic acid, [2-[[2-[[(2-chloro-3,4-dimethoxybenzoyl)(3-methylbutyl)amino]methyl]-4,5-dimethyl-1H-imidazol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 352437-17-3 CAPLUS
CN Benzoic acid, 2-[[2-[[(2-chloro-3,4-dimethoxybenzoyl)(3-methylbutyl)amino]methyl]-4,5-dimethyl-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 352437-18-4 CAPLUS
CN Benzamide, 2-chloro-N-[[1-[[2-(cyanomethoxy)phenyl]methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-19-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-dimethyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-20-8 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-dimethyl-1-[(2-methylphenyl)methyl]-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-21-9 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-dimethyl-1-[[2-(trifluoromethyl)phenyl]methyl]-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-25-3 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-diethyl-1-(2-pyridinylmethyl)-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-26-4 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-dimethyl-1-(2-quinolinylmethyl)-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-27-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-diethyl-1-[(5-ethyl-2-methoxyphenyl)methyl]-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-28-6 CAPLUS
CN Benzamide, N-[[1-[(5-bromo-2-hydroxyphenyl)methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-2-chloro-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-29-7 CAPLUS
CN Benzamide, 2-chloro-N-[[1-[(5-chloro-2-hydroxyphenyl)methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-31-1 CAPLUS
CN Benzamide, N-[[1-[[2-(aminocarbonyl)phenyl]methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-2-chloro-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-33-3 CAPLUS
CN Benzamide, N-[[1-[[2-(aminosulfonyl)phenyl]methyl]-4,5-dimethyl-1H-imidazol-2-yl]methyl]-2-chloro-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-35-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4,5-dimethyl-1-[[2-(1H-tetrazol-5-yl)phenyl]methyl]-1H-imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-42-4 CAPLUS
CN Benzamide, 2-chloro-N-[[1-[(2-hydroxyphenyl)methyl]-4,5-dimethyl-1H-

imidazol-2-yl]methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-43-5 CAPLUS
CN Acetic acid, [2-[[2-[[(2-chloro-3,4-dimethoxybenzoyl)(3-methylbutyl)amino]methyl]-4,5-dimethyl-1H-imidazol-1-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT **352437-39-9P 352437-40-2P 352437-41-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of substituted imidazoles as selective modulators of bradykinin B2 receptors)
RN 352437-39-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-[(2-chlorophenyl)methyl]-4,5-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-40-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4,5-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 352437-41-3 CAPLUS
CN Benzamide, 2-chloro-N-[(4,5-dimethyl-1H-imidazol-2-yl)methyl]-3,4-dimethoxy-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:283789 CAPLUS
DOCUMENT NUMBER: 134:311210
TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments
INVENTOR(S): Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thurieau, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		

PRIORITY APPLN. INFO.:
FR 1999-12643 A 19991011
FR 2000-10151 A 20000801
FR 2000-11169 A 20000901

OTHER SOURCE(S): MARPAT 134:311210
GI











II

AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH2)n-CR1R2-Q [I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, esp. a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = esp. H or alkyl, or also aryl or substituted alkyl; X = esp. NH or S, or also substituted NH; Y = O or S; n = 0-6; R1, R2 = esp. H, alkyl, or cycloalkyl; Q = NR3R4 or OR5; R3 and R4 = esp. H, alkyl, cycloalkyl, alkynyl, cyanoalkyl alkoxycarbonyl, aralkoxycarbonyl or (cycloalkyl)oxycarbonyl; R5 = H, alkyl, alkynyl, or cyanoalkyl]. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH2CONH2, which was converted to the thioamide with (P2S5)2 in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and salification (92%), gave thiazole deriv. II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial prepns. with IC50 < 10 .mu.M. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex prepns., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.

IT **252302-96-8P**, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335246-82-7P**, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 252302-96-8 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-82-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-.alpha.-hexyl- (9CI) (CA INDEX NAME)



IT **252279-09-7**, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335246-52-1**, (1-Benzyl-4-phenyl-1H-imidazol-2-yl)methanamine **335246-59-8**, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine **335246-68-9**, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-52-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-59-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-68-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **252309-65-2P**, (1S)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **280775-44-2P**, N-Benzyl(4-phenyl-1H-imidazol-2-yl)methanamine **335242-80-3P**, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-1H-imidazole-2-methanamine **335242-96-1P**, (1R)-N-Benzyl-1-(1-benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine **335242-97-2P**, (R,S)-N-Benzyl-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335242-98-3P**, N-Benzyl-N-[[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methyl]-1-hexanamine **335242-99-4P**, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine **335243-00-0P**, (R,S)-N,N-Dihexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-02-2P**, (1-Benzyl-4-phenyl-1H-imidazol-2-yl)-N,N-dimethylmethanamine **335243-03-3P**, (1R)-N-Benzyl-2-(1H-indol-3-yl)-N-methyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335243-04-4P**, (1R)-2-(1H-Indol-3-yl)-N-(2-phenylethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335243-06-6P**, (1R)-tert-Butyl [1-(4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethyl]carbamate **335243-07-7P**, (4-Phenyl-1H-imidazol-2-yl)methanamine hydrochloride **335243-09-9P**, N-[(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine hydrochloride **335243-10-2P**, (R,S)-tert-Butyl [1-(4-phenyl-1H-imidazol-2-yl)heptyl]carbamate **335243-11-3P**, [4-[1,1'-Biphenyl]-4-yl-1-methyl-1H-imidazol-2-yl]methanamine hydrochloride **335243-14-6P**, (R,S)-N-[2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-butanamine **335243-15-7P**, (R,S)-4-[2-[1-[(tert-Butoxycarbonyl)amino]pentyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335243-16-8P**, (R,S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-pentanamine **335243-19-1P**, (R,S)-tert-Butyl [1-(4-phenyl-1H-imidazol-2-yl)hexyl]carbamate **335243-20-4P**, (R,S)-N-Hexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-21-5P**, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine hydrochloride **335243-22-6P**, (R,S)-N-Benzyl-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride

335243-23-7P, (R,S)-N-(2,6-Dichlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-24-8P**, (R,S)-N-(4-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-25-9P**, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride **335243-26-0P**, (R,S)-N-(2-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-27-1P**, (R,S)-N-(2-Fluorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-28-2P**, (R,S)-N-Butyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-29-3P**, (R,S)-N-Isopentyl-N-[1-(4-phenyl-1H-imidazol-2-yl)heptyl]amine **335243-30-6P**, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-N-hexyl-1-heptanamine **335243-31-7P**, (R,S)-N-Pentyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-33-9P**, (R,S)-N-Benzyl-1-[4-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine **335243-34-0P**, Butyl [[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methyl]carbamate **335243-44-2P**, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride **335243-47-5P**, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride **335243-49-7P**, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine **335243-50-0P**, (1R)-tert-Butyl [2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate **335243-51-1P**, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride **335243-52-2P**, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide **335243-53-3P**, (1R)-Benzyl [2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate **335243-56-6P**, (1R)-tert-Butyl [2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]carbamate **335243-57-7P**, tert-Butyl [(4-phenyl-1H-imidazol-2-yl)methyl]carbamate **335243-58-8P**, tert-Butyl [(1-benzyl-4-phenyl-1H-imidazol-2-yl)methyl]carbamate **335243-59-9P**, (R,S)-N-Benzyl-2-(6-fluoro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335243-60-2P**, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride **335243-61-3P**, (1-Benzyl-4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride **335243-62-4P**, (1R)-2-(1H-Indol-3-yl)-N-(2-phenoxyethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335243-63-5P**, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylamine hydrochloride **335243-64-6P**, N-Benzyl(1-benzyl-4-phenyl-1H-imidazol-2-yl)methanamine **335243-65-7P**, (1R)-2-(1-Benzothien-3-yl)-N-benzyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **335243-68-0P*****, **(R,S)-tert-Butyl [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate** *****335243-72-6P**, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride **335243-87-3P**, 4-[2-[[(tert-Butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335243-90-8P**, 4-[1-Benzyl-2-[[(tert-butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335243-91-9P**, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]methanamine hydrochloride **335243-92-0P**, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine hydrochloride **335243-93-1P**, [1-Benzyl-4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine hydrochloride **335243-95-3P**, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335243-96-4P**, 4-[2-[[(tert-Butoxycarbonyl)amino]methyl]-1-methyl-1H-imidazol-4-yl]-1,1'-biphenyl **335244-00-3P**, (1R)-tert-Butyl [2-(1H-indol-3-yl)-1-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl]carbamate **335244-02-5P**, 4-[2-[[(tert-Butoxycarbonyl)(methyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335244-06-9P**, (1R)-2-(1H-Indol-3-yl)-1-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride **335244-10-5P**, tert-Butyl methyl[(5-methyl-4-phenyl-1H-imidazol-2-yl)methyl]carbamate **335244-12-7P**, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine hydrochloride **335244-17-2P**, N-Methyl-(5-methyl-4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride **335244-29-6P**, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-

yl]methanamine hydrochloride **335244-35-4P**, (R,S)-tert-Butyl [1-(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate **335244-36-5P**, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-pentanamine hydrochloride **335244-42-3P**, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)pentylamine hydrochloride **335244-43-4P**, (R,S)-tert-Butyl [1-[4-(4-methylphenyl)-1H-imidazol-2-yl]heptyl]carbamate **335244-44-5P**, (R,S)-tert-Butyl [1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]heptyl]carbamate **335244-45-6P**, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-46-7P**, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride **335244-47-8P**, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-pentanamine **335244-48-9P**, (R,S)-tert-Butyl [1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]carbamate **335244-49-0P**, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-50-3P**, (R,S)-tert-Butyl [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]carbamate **335244-51-4P**, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride **335244-52-5P**, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-53-6P**, (R,S)-4-[2-[1-[(tert-Butoxycarbonyl)amino]heptyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335244-55-8P**, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine acetate **335244-56-9P**, 4-[2-[(1S)-1-[(tert-Butoxycarbonyl)amino]propyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335244-57-0P**, (R,S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine **335244-58-1P**, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine hydrochloride **335244-60-5P**, (1S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine **335244-62-7P**, (R,S)-N-Benzyl-1-[4-(4-methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-63-8P**, (R,S)-N-Benzyl-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine **335244-64-9P**, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-hexanamine **335244-67-2P**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile hydrochloride **335244-68-3P**, (R,S)-1-[4-(4-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine **335244-69-4P**, (1R)-tert-Butyl [1-(4-phenyl-1H-imidazol-2-yl)butyl]carbamate **335244-70-7P**, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]butyl]-1H-imidazol-4-yl]-1,1'-biphenyl **335244-71-8P**, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine hydrochloride **335244-72-9P**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol hydrochloride **335244-73-0P**, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride **335244-74-1P**, (R,S)-N-Benzyl-1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine **335244-75-2P**, (1R)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine **335244-76-3P**, (1R)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine **335244-77-4P**, (R,S)-N-(3-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335244-78-5P**, (R,S)-N-Benzyl-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine **335244-79-6P**, (R,S)-4-[2-[1-(Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile **335244-80-9P**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride **335244-82-1P**, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-83-2P**, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-84-3P**, N-[(1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]propyl]-1-butanamine **335244-86-5P**, (R,S)-N-[1-(4-Phenyl-1H-imidazol-2-yl)heptyl]-N-propylamine **335244-87-6P**, (R,S)-N-Benzyl-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-88-7P**, (R,S)-4-[2-[1-(Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile hydrochloride **335244-89-8P**, (R,S)-N-(4-Methoxybenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine **335244-90-1P**, (R,S)-N-Benzyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine

hydrochloride **335244-91-2P**, (R,S)-N-Benzyl-1-[4-(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-92-3P**, (R,S)-N-Benzyl-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]heptyl]amine hydrochloride **335244-93-4P**, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride **335244-97-8P**, (R,S)-N-Isobutyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine acetate **335244-99-0P**, (R,S)-N-Benzyl-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine **335245-11-9P**, (R,S)-N-Isopropyl-N-[1-(4-phenyl-1H-imidazol-2-yl)heptyl]amine **335245-17-5P**, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethylamine hydrochloride **335245-27-7P**, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine hydrochloride
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 252309-65-2 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280775-44-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-80-3 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[(methylamino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335242-96-1 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335242-97-2 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-phenyl-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-98-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-99-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-00-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N,.alpha.-trihexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-02-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N-dimethyl-4-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-03-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-methyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-04-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-06-6 CAPLUS
CN Carbamic acid, [(1R)-1-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-07-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-09-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335243-10-2 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-11-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-1-methyl-,

hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-14-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335243-15-7 CAPLUS
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-16-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-19-1 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-20-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N,.alpha.-dihexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-21-5 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-22-6 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-23-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-24-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-25-9 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-26-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-27-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-28-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-butyl-.alpha.-hexyl-4-phenyl- (9CI) (CA

INDEX NAME)



RN 335243-29-3 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-30-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,.alpha.-dihexyl- (9CI) (CA INDEX NAME)



RN 335243-31-7 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-33-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)



RN 335243-44-2 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-47-5 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-49-7 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-methyl-5-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-50-0 CAPLUS

CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-51-1 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335243-52-2 CAPLUS
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-56-6 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-57-7 CAPLUS
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-58-8 CAPLUS
CN Carbamic acid, [[4-phenyl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-59-9 CAPLUS
CN 1H-Indole-3-ethanamine, 6-fluoro-.alpha.-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335243-61-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-1-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-62-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-63-5 CAPLUS

CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335243-64-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-65-7 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-68-0 CAPLUS
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-72-6 CAPLUS

CN 1H-Indole-3-ethanamine, 6-chloro-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-87-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-90-8 CAPLUS
CN Carbamic acid, [[4-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-91-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 335243-92-0 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-93-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335243-95-3 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-96-4 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1-methyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-00-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-02-5 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-06-9 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(1-methyl-4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335244-10-5 CAPLUS
CN Carbamic acid, methyl[(4-methyl-5-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-12-7 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-17-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N,4-dimethyl-5-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-29-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-35-4 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-36-5 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-butyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-42-3 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-43-4 CAPLUS
CN Carbamic acid, [1-[4-(4-methylphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-44-5 CAPLUS
CN Carbamic acid, [1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-45-6 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-46-7 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-47-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-butyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-48-9 CAPLUS
CN Carbamic acid, [1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-49-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-50-3 CAPLUS
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-51-4 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-52-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-53-6 CAPLUS
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-55-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-.alpha.-hexyl-N-(phenylmethyl)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-54-7
CMF C23 H28 Br N3



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 335244-56-9 CAPLUS
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-57-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-58-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-ethyl-, hydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335244-60-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-ethyl-N-(phenylmethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-62-7 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-63-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-64-9 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335244-69-4 CAPLUS
CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-70-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-71-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-propyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335244-72-9 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-73-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-.alpha.-propyl-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335244-74-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-75-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-76-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-77-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-78-5 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-79-6 CAPLUS
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335244-80-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-82-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 335244-83-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-84-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl-.alpha.-ethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-86-5 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-phenyl-N-propyl- (9CI) (CA INDEX NAME)



RN 335244-87-6 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

RN 335244-88-7 CAPLUS
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-89-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-90-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-.alpha.-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-91-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-.alpha.-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-92-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-.alpha.-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-93-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-.alpha.-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-97-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-N-(2-methylpropyl)-4-phenyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-96-7
CMF C20 H31 N3



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 335244-99-0 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335245-11-9 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335245-17-5 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-.alpha.-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335245-27-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-.alpha.-hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

IT **175531-38-1**, (4-Phenyl-1H-imidazol-2-yl)methanamine **218944-40-2**, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine **218944-41-3**, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine **252279-11-1**, (1R)-1-(4-tert-Butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethylamine **252279-15-5**, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine **252301-86-3**, (R,S)-tert-Butyl [5-(benzylamino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate **252302-55-9**, N-[(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-

yl)ethyl]-1-hexanamine **252303-16-5**, (1R)-N-(Cyclohexylmethyl)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine **252306-13-1**, (R,S)-N1-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanediamine **252314-87-7**, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenylurea **335243-70-4**, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzenecarboximidamide **335243-71-5**, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxybenzenecarboximidamide **335244-54-7**, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-20-3**, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine **335246-23-6**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol **335246-40-7**, [4-[1,1'-Biphenyl]-4-yl-1-methyl-1H-imidazol-2-yl]methanamine **335246-41-8**, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine **335246-42-9**, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine **335246-48-5**, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine **335246-51-0**, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine **335246-54-3**, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine **335246-58-7**, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]methanamine **335246-60-1**, [1-Benzyl-4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine **335246-62-3**, N-Methyl-(5-methyl-4-phenyl-1H-imidazol-2-yl)methanamine **335246-69-0**, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-70-3**, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine **335246-71-4**, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine **335246-72-5**, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine **335246-73-6**, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-74-7**, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine **335246-76-9**, (R,S)-N-Benzyl-1-[4-(4-methylphenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-77-0**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile **335246-78-1**, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine **335246-79-2**, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine **335246-80-5**, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline **335246-83-8**, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-84-9**, (R,S)-N-Benzyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-85-0**, (R,S)-N-Benzyl-1-[4-(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-86-1**, (R,S)-N-Benzyl-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]heptyl]amine **335246-87-2**, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine **335246-91-8**, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethylamine **335246-97-4**, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 175531-38-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



RN 218944-40-2 CAPLUS
CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-

2-yl]methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 252279-11-1 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252301-86-3 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(phenylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX

NAME)



RN 252302-55-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-16-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252306-13-1 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 252314-87-7 CAPLUS
CN Urea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-70-4 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-71-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335244-54-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-20-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-

imidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 335246-23-6 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 335246-40-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-1-methyl- (9CI) (CA INDEX NAME)



RN 335246-41-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-pentyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-42-9 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-48-5 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-methyl-5-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-.alpha.-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-58-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)



RN 335246-60-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-62-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N,4-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-ethyl-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-76-9 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-.alpha.-propyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335246-84-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-85-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-.alpha.-hexyl-N-

(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-86-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-.alpha.-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-.alpha.-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 335246-97-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-.alpha.-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



IT **335247-31-9P**, tert-Butyl [1-(4-cyclohexyl-1H-imidazol-2-yl)heptyl]carbamate **335247-32-0P**, 1-(4-Cyclohexyl-1H-imidazol-2-

yl)-1-heptanamine **335247-35-3P**, tert-Butyl [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 335247-31-9 CAPLUS
CN Carbamic acid, [1-(4-cyclohexyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335247-32-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-cyclohexyl-.alpha.-hexyl- (9CI) (CA INDEX NAME)



RN 335247-35-3 CAPLUS
CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **335247-36-4**, (1R)-1-(1-Benzyl-4-tert-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine **335247-37-5**, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine
RL: RCT (Reactant)
(precursor; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 335247-36-4 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-37-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:527784 CAPLUS
DOCUMENT NUMBER: 135:251427
TITLE: Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity
AUTHOR(S): Poitout, Lydie; Roubert, Pierre; Contour-Galcera, Marie-Odile; Moinet, Christophe; Lannoy, Jacques; Pommier, Jacques; Plas, Pascale; Bigg, Dennis; Thurieau, Christophe
CORPORATE SOURCE: Institut Henri Beaufour, Les Ulis, F-91966, Fr.
SOURCE: Journal of Medicinal Chemistry (2001), 44(18), 2990-3000
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Using a soln.-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepd., and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were detd. Imidazolyl derivs. were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype. Further modifications of these structures led to a more potent class of ligands, the tetrahydro-.beta.-carboline derivs. Among these, compds. BN81644 and BN81674 bind selectively and with high affinity to the sst3 receptor subtype (Ki = 0.64 and 0.92 nM, resp.). Furthermore, BN81644 and BN81674 reverse the inhibition of cAMP accumulation induced by 1 nM somatostatin via sst3 receptors, with IC50 = 2.7 and 0.84 nM, resp. The most potent compd. BN81674 was shown to be a competitive antagonist of human sst3 receptors by increasing the EC50 of SRIF-14-mediated inhibition of cAMP accumulation with a KB of 2.8 nM (where KB is the concn. of antagonist that shifts the agonist dose-response 2-fold). These new derivs. are, to the authors knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiol. role of sst3 receptors.

IT **252279-08-6P 252279-09-7P 252279-24-6P**
335243-50-0P 349668-19-5P, tert-Butyl (1S)-2-(1H-Indol-3-yl)-1-(4-phenyl 1H-imidazol-2-yl)ethylcarbamate
361576-57-0P 361576-59-2P 361576-60-5P

361576-63-8P 361576-64-9P 361576-65-0P
361576-66-1P 361576-67-2P 361576-69-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(identification of potent non-peptide somatostatin receptor antagonists with sst3 selectivity)

RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-24-6 CAPLUS
CN Carbamic acid, [(1R)-2-benzo[b]thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349668-19-5 CAPLUS
CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 361576-57-0 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-59-2 CAPLUS
CN Carbamic acid, [2-(5-methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-60-5 CAPLUS
CN Carbamic acid, [2-(5-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-63-8 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 361576-64-9 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 361576-65-0 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-5-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361576-66-1 CAPLUS
CN 1H-Indole-3-ethanamine, 5-methyl-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361576-67-2 CAPLUS
CN 1H-Indole-3-ethanamine, 5-chloro-.alpha.-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361576-69-4 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-(benzo[b]thien-3-ylmethyl)-4-phenyl-, dihydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:279029 CAPLUS
DOCUMENT NUMBER: 135:107278
TITLE: Novel non-peptide ligands for the somatostatin sst3 receptor
AUTHOR(S): Moinet, C.; Contour-Galcera, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thurieau, C.
CORPORATE SOURCE: ZA de Courtaboeuf, Institut Henri Beaufour, Les Ulis, F-91966, Fr.
SOURCE: Bioorg. Med. Chem. Lett. (2001), 11(8), 991-995
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of imidazole derivs. has been prepd. using high throughput parallel synthesis. Several compds. showed high affinity (Ki in 10-6-10-8 M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hsst3).

IT **252279-09-7P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)

RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252292-71-0P 252308-47-7P** 252309-00-5P
252309-02-7P 252309-03-8P 252309-04-9P
252309-05-0P 252309-06-1P 252309-07-2P
252311-56-1P 335243-50-0P 335243-53-3P
349668-18-4P 349668-19-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)

RN 252292-71-0 CAPLUS

CN Urea, N-(2,4-difluorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252308-47-7 CAPLUS

CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-00-5 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252309-02-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252309-03-8 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HI

RN 252309-04-9 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252309-05-0 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252309-06-1 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252309-07-2 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 252311-56-1 CAPLUS
CN Urea, N-(1,1-dimethylethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349668-18-4 CAPLUS
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

RN 349668-19-5 CAPLUS
CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:177457 CAPLUS
DOCUMENT NUMBER: 135:19604
TITLE: Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5
AUTHOR(S): Contour-Galcera, M.-O.; Poitout, L.; Moinet, C.; Morgan, B.; Gordon, T.; Roubert, P.; Thurieau, C.
CORPORATE SOURCE: Institut Henri Beaufour, Les Ulis, F-91966, Fr.
SOURCE: Bioorg. Med. Chem. Lett. (2001), 11(5), 741-745
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new prepn. of trisubstituted imidazopyrazines and dihydroimidazopyrazines via parallel synthesis using amino acids and bromo ketones resulted in the discovery of non-peptidic sst5 selective agonists.

IT **342648-61-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5)

RN 342648-61-7 CAPLUS
CN Carbamic acid, [4-(2,6-diphenylimidazo[1,2-a]pyrazin-8-yl)butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:348345 CAPLUS
DOCUMENT NUMBER: 135:153081
TITLE: Structure-activity studies of peptidomimetics containing azole residues: effects on cholinergic neurotransmission
AUTHOR(S): Stanchev, Mincho S.; Bocheva, Adriana I.; Angelov, Todor B.; Todorov, Simeon A.; Pajpanova, Tamara I.; Golovinsky, Evgeny V.

CORPORATE SOURCE: Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, 1113, Bulg.
SOURCE: Bulg. Chem. Commun. (2001), 33(1), 65-72
CODEN: BCHCE4; ISSN: 0324-1130
PUBLISHER: Bulgarian Academy of Sciences and the Bulgarian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Thiazole and oxazole derivs. of the amino acids canavanine and leucine have been synthesized and their biol. activity has been studied. In vitro expts. have been performed to investigate the structure-activity relationship on elec.-evoked contractions of smooth muscle with predominant cholinergic neurotransmission. However, further studies are necessary to elucidate the precise mechanisms of action of the new azole amino-acid analogs on the smooth-muscle neurotransmission.

IT **352564-27-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and effects on cholinergic neurotransmission of azole derivs. of leucine and canavanine)
RN 352564-27-3 CAPLUS
CN 5-Oxa-2,4,9-triazadecanedioic acid, 3-imino-8-[4-(methoxycarbonyl)-1H-imidazol-2-yl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT **352564-34-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and effects on cholinergic neurotransmission of azole derivs. of leucine and canavanine)
RN 352564-34-2 CAPLUS
CN 5-Oxa-2,4,9-triazadecanedioic acid, 8-(4-carboxy-1H-imidazol-2-yl)-3-imino-, 1,10-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:457071 CAPLUS
DOCUMENT NUMBER: 133:89553
TITLE: Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
INVENTOR(S): Gordon, Thomas B.; Morgan, Barry A.
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.

Searched by Barb O'Bryen STIC 308-4291

SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039130	A2	20000706	WO 1999-US31302	19991230
WO 2000039130	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140942	A2	20011010	EP 1999-968984	19991230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001003281	A	20010829	NO 2001-3281	20010629

PRIORITY APPLN. INFO.:
US 1998-114301 P 19981231
US 1998-224428 A1 19981231
WO 1999-US31302 W 19991230

OTHER SOURCE(S): MARPAT 133:89553
GI



I

AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepd. as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (prepn. given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

IT **280775-08-8P 280775-09-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazopyrazines, imidazobenzodiazepines, and related compds. as prenyl transferase inhibitors)

RN 280775-08-8 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-butyl-7-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]acetyl]-5,6,7,8-tetrahydro-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 280775-09-9 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-butyl-7-[[1-[(4-cyanophenyl)methyl]-1H-imidazol-5-yl]acetyl]-5,6,7,8-tetrahydro-2-phenyl- (9CI) (CA INDEX NAME)



IT **280775-81-7**
RL: RCT (Reactant)
(prepn. of imidazopyrazines, imidazobenzodiazepines, and related compds. as prenyl transferase inhibitors)

RN 280775-81-7 CAPLUS
CN Carbamic acid, [[4-(2-methoxyphenyl)-1H-imidazol-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT **280775-35-1P 280775-44-2P 280775-53-3P**
280775-54-4P 280775-60-2P 280775-61-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of imidazopyrazines, imidazobenzodiazepines, and related compds. as prenyl transferase inhibitors)

RN 280775-35-1 CAPLUS
CN Carbamic acid, [(1S)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280775-44-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 280775-53-3 CAPLUS
CN Carbamic acid, [[4-(2-methoxyphenyl)-1-(2-oxohexyl)-1H-imidazol-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 280775-54-4 CAPLUS
CN Imidazo[1,2-a]pyrazine, 6-butyl-5,6,7,8-tetrahydro-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 280775-60-2 CAPLUS
CN Carbamic acid, [[1-[(2-fluorophenyl)methyl]-4-(2-methoxyphenyl)-1H-imidazol-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 280775-61-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-[(2-fluorophenyl)methyl]-4-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)



L35 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:391139 CAPLUS
DOCUMENT NUMBER: 133:129526
TITLE: Computer prediction of biological activity spectra for low-molecular peptides and peptidomimetics
AUTHOR(S): Martynova, N. B.; Filimonov, D. A.; Poroikov, V. V.
CORPORATE SOURCE: Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, 119832, Russia
SOURCE: Russ. J. Bioorg. Chem. (2000), 26(5), 297-305
CODEN: RJBCET; ISSN: 1068-1620
PUBLISHER: MAIK Nauka/Interperiodica
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The wide variety of the biol. effects of peptides and their high activity are the main reasons for the search for new basic drug structures among them. The most promising compds. can be selected using the PASS computer system (Prediction of Activity Spectra for Substances). This system was originally developed to predict the activities of low-mol. "drug-like" org. compds. Its predictive capacity is described here by the example of 134 peptides and peptidomimetics with nine known biol. activities. Its av. predictive power is shown to be approx. 97%. Such an accuracy demonstrates that computer prediction can be applied both to the evaluation of effects and mechanisms of action of endogenous and synthetic peptides and to the screening of new therapeutic agents among the most promising basic structures.

IT **168468-58-4 168468-74-4 168468-80-2 168468-84-6 172922-37-1 172922-38-2**

172922-39-3
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(endothelin receptor antagonist; computer prediction of biol. activity spectra for low-mol. peptides and peptidomimetics)

RN 168468-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-74-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylmethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-80-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexyloxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-84-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-37-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-38-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-39-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2R)-2-[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:795813 CAPLUS
DOCUMENT NUMBER: 132:35702
TITLE: Preparation of imidazolyl-.beta.-carbolines and related compounds as somatostatin receptor mediators and sodium channel blockers.
INVENTOR(S): Thurieau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-odile; Moinet, Christophe Philippe; Gordon, Thomas D.; Morgan, Barry A.; Bigg, Dennis C. H.; Pommier, Jacques
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques S. A., Fr.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964420	A1	19991216	WO 1999-US12874	19990608

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9945536	A1	19991230	AU 1999-45536		19990608
EP 1086101	A1	20010328	EP 1999-928479		19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
NO 2000006268	A	20010129	NO 2000-6268		20001211
PRIORITY APPLN. INFO.:			US 1998-89180	P	19980612
			US 1998-97297	A1	19980612
			WO 1999-US12874	W	19990608

OTHER SOURCE(S): MARPAT 132:35702
GI



I

AB Title compds. [I; dotted lines = optional double bonds; X = N, NR4; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, (CH2)mOZ1, etc.; Z1 = (substituted) alkyl, benzothienyl, Ph, naphthyl, benzofuryl, thienyl, indolyl, etc.; R2 = alkyl, ACO2Z5, (substituted) Ph, etc.; Z5 = H, alkyl, aryl, aralkyl; R3 = H; R4 = CYNX1X2, COX2, X2; Y = O, S; X2 = (CH2)mY1X3; X3 = H, (substituted) alkyl, cycloalkyl, alkoxy, aryloxy, alkylamino, Ph, etc.; Y1 = O, S, NH, bond; R5 = alkyl, cycloalkyl, (substituted) Ph, furyl, thienyl, pyrrolyl, pyridinyl, etc.; R6 = H, PhSO2; R7 = H, alkyl, alkoxyalkyl, dialkylaminoalkyl; X1 = H, Cl, F, Br, iodo, NO2, OH, CF3, alkyl, etc.; m = 0-6; n = 1-5], were prepd. as drugs (no data). Thus, 2-[1(S)-amino-2-(3-indolyl)ethyl]-4-phenyl-1H-imidazole in CHCl3 was treated with p-anisaldehyde and CF3CO2H followed by 2 days stirring to give a residue which was stirred overnight with aminomethylpolystyrene resin in THF to give 78% 1,2,3,4-tetrahydro-1(RS)-(4-methoxyphenyl)-3(S)-(4-phenyl-1H-imidazol-2-yl)-9H-pyrido[3,4-b]indole.

IT **252279-08-6 252279-09-7 252279-10-0**
252279-11-1 252279-12-2 252279-13-3
252279-14-4 252279-15-5 252279-34-8
RL: RCT (Reactant)
(prepn. of imidazolyl-.beta.-carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)

RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-(4-phenyl-1H-imidazol-2-yl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-10-0 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-11-1 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(1,1-dimethylethyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-12-2 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-13-3 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-14-4 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, .alpha.-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-34-8 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-(benzo[b]thien-3-ylmethyl)-4-phenyl-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **252279-23-5P 252279-24-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of imidazolyl-.beta.-carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)
RN 252279-23-5 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-(benzo[b]thien-3-ylmethyl)-4-phenyl-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 252279-24-6 CAPLUS
CN Carbamic acid, [(1R)-2-benzo[b]thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:613914 CAPLUS
DOCUMENT NUMBER: 131:257875
TITLE: Preparation of heterocyclyl phosphotyrosine derivatives as SH2-mediated signal transduction inhibitors
INVENTOR(S): Buchanan, John; Bohacek, Regine; Vu, Chi B.; Luke, George P.
PATENT ASSIGNEE(S): Ariad Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947529	A1	19990923	WO 1999-US5970	19990318
W: CA, CZ, JP, MX, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1064289	A1	20010103	EP 1999-912685	19990318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1998-78412 P 19980318
US 1998-108084 P 19981112
WO 1999-US5970 W 19990318

OTHER SOURCE(S): MARPAT 131:257875
GI



I



II

AB Heterocyclic phosphotyrosine derivs. were prepd. for inhibiting intracellular signal transduction, esp. intracellular signal transduction mediated by a PDGF receptor protein, EGF receptor protein, HER2/Neu receptor protein, fibroblast growth factor receptor protein, focal adhesion kinase protein, p130 protein, or p68 protein. For example, BOC-Tyr(PO3Bn2)-OH (BOC = tert-butoxycarbonyl; Bn = benzyl) and the thiazolylamine salt (I).cntdot.TFA (four step prepn. given) were coupled, the phosphate deprotected, the amine acylated, and the carboxylic acid deprotected to form the title compd. (II). In an assay for binding affinities to Src SH2, thirteen compds. of the invention were detd. to have IC50 values of < 50.mu.M. In an assay for binding affinities to Zap-70 SH2, fourteen compds. of the invention exhibited IC50 values of < 50.mu.M. This invention also relates to pharmaceutical compns. contg. the compds. and prophylactic and therapeutic methods involving pharmaceutical and veterinary administration of the compds. for proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, cardiovascular disease, or immunosuppression.

IT **244207-87-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of heterocyclyl phosphotyrosine derivs. as SH2-mediated signal transduction inhibitors)
RN 244207-87-2 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-[(1S)-1-[[(2S)-2-(acetylamino)-1-oxo-3-[4-(phosphonooxy)phenyl]propyl]amino]propyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:648054 CAPLUS
DOCUMENT NUMBER: 132:36007
TITLE: Synthesis of thiazole, imidazole and oxazole containing amino acids for peptide backbone modification
AUTHOR(S): Stankova, Ivanka G.; Videnov, Georgi I.; Golovinsky, Evgeny V.; Jung, Guenther
CORPORATE SOURCE: Department of Chemistry, Southwest University "N. Rilski", Blagoevgrad, 2700, Bulg.
SOURCE: J. Pept. Sci. (1999), 5(9), 392-398
CODEN: JPSIEI; ISSN: 1075-2617
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel 5-membered heterocyclic ring-contg. amino acid building blocks are synthesized. These can be incorporated into analogs of peptide antibiotics such as microcin B17, which is a potent DNA-gyrase inhibitor that exhibits eight thiazole and oxazole moieties. In particular, the syntheses of imidazole and bisoxazole amino acids as novel peptidomimetics are reported, this includes a new procedure for the oxidative conversion of the intermediates oxazoline, imidazoline as well as oxazole-oxazoline into the corresponding heteroarom. compds. A mixt. of DBU/CCl4/MeCN and pyridine proved to be a very effective and mild agent for this oxidn. step.
IT **252348-76-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of thiazole, imidazole and oxazole contg. amino acids useful for peptide synthesis)
RN 252348-76-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:27832 CAPLUS
DOCUMENT NUMBER: 130:81398
TITLE: Novel 2-(iminomethyl)aminophenyl derivatives as NO synthase inhibitors and traps for radical oxygen species
INVENTOR(S): Auvin, Serge; Harnett, Jeremiah; Bigg, Dennis; Chabrier De Lassauniere, Pierre-Etienne
PATENT ASSIGNEE(S): Societe De Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
TW 422842	B	20010221	TW 1998-87109245	19980610
AU 9882189	A1	19990104	AU 1998-82189	19980615
AU 737964	B2	20010906		
EP 991654	A1	20000412	EP 1998-932205	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9810197	A	20000808	BR 1998-10197	19980615
ZA 9805392	A	19990120	ZA 1998-5392	19980619
NO 9906208	A	20000215	NO 1999-6208	19991215
US 2002007062	A1	20020117	US 2001-882264	20010615

PRIORITY APPLN. INFO.:

FR 1997-7701	A	19970620
FR 1997-3528	A	19970324
WO 1998-FR288	W	19980216
WO 1998-FR1250	W	19980615
US 1999-381749	A2	19990922
US 1999-456205	A3	19991207

OTHER SOURCE(S): MARPAT 130:81398
GI



HI

I

AB Amidines AXHetYC6H4N:CBNH2 [A = H, (un)substituted HOC6H4, 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl; B = (un)substituted alkyl, Ph, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl; X = (un)substituted CONHX1, NHCOX1, CH:, CO, bond; X1 = (CH2)n; n = 0-6; Y = Y1, CONHY1, NHCOY1, COY1, Y1CO, (un)substituted NHY1, Y1NH, Y1CH2NHCO, OY1, SY1, Y1S, Y1OY1, Y1NHY1; Y1 = (CH2)n; Het = (un)substituted heterocyclic] were prepd. for use as NO synthetase inhibitors and reactive oxygen species traps. Thus, 4-FC6H4NO2 was treated with imidazole and the 1-p-nitrophenylimidazole reduced to the amine and treated with the thiophene fragment to give the amidine I. I had an NO synthetase-inhibiting IC50 < 3.5 .mu.M.

IT **218944-36-6P 218944-40-2P** 218944-41-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of novel 2-(iminomethyl)aminophenyl derivs. as NO synthase inhibitors and traps for radical oxygen species)

RN 218944-36-6 CAPLUS
CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 218944-40-2 CAPLUS
CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **218944-42-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel 2-(iminomethyl)aminophenyl derivs. as NO synthase inhibitors and traps for radical oxygen species)
RN 218944-42-4 CAPLUS
CN Benzamide, N-[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[(imino-2-thienylmethyl)amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:424263 CAPLUS
DOCUMENT NUMBER: 129:95714
TITLE: Preparation of new heterocyclic amides as nitric oxide production inhibitors
INVENTOR(S): Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hitoshi; Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei; Oku, Teruo
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Yatabe, Yoshiko; Itoh, Yoshikuni; Inoue, Takayuki; Hamashima, Hitoshi; Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei; Oku, Teruo
SOURCE: PCT Int. Appl., 533 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9749680 A1 19980715 AU 1997-49680 19971120
EP 946587 A2 19991006 EP 1997-912529 19971120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001505585 T2 20010424 JP 1998-527528 19971120
ZA 9710603 A 19980625 ZA 1997-10603 19971125
PRIORITY APPLN. INFO.: AU 1996-4219 A 19961216
AU 1997-5929 A 19970401
AU 1997-9030 A 19970909
WO 1997-JP4243 W 19971120

OTHER SOURCE(S): MARPAT 129:95714
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = S, NR9; Y = CHR3, (un)substituted phenylene; R1 = (un)substituted indolyl, (un)substituted benzofuranyl; R2 = H, phenyl-lower alkyl; R3 = H, (CH2)nR6; R4 = H, (un)substituted Ph, (un)substituted pyridyl; R5 = H, imidazolyl, Ph, nitrophenyl, phenyl-lower alkyl, optionally esterified carboxy, CONR7R8; R4R5 = CH:CHCH:CH; R6 = optionally protected OH, acyl, carboxy, acylamino, lower alkoxy, phenyl-lower alkoxy, lower alkylthio, (un)substituted Ph; R7, R8 = independently H, Ph, phenyl-lower alkyl, lower alkyl, lower alkoxy; R9 = H, lower alkyl, lower cycloalkyl, (un)substituted benzyl; m = 0, 1; n = 0-3] and pharmaceutically acceptable salts thereof are described as strong inhibitors of the prodn. of nitric oxide. Compds. I are useful for prevention and treatment of nitric oxide-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, post-herpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in humans and animals. Thus, 2-step cyclocondensation of amino ketone II (prepn. given) with protected 3-(2-pyridyl)-L-alanine and methylamine gave protected imidazole III (Boc = Me3CO2C). Deprotection of III followed by acylation with indole-2-carboxylic acid gave desired compd. IV. IV inhibited nitric oxide prodn. 100% in murine macrophage cell line RAW264.7 at 10-5 M.

IT **209525-11-1P 209525-32-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of new heterocyclic amides as nitric oxide prodn. inhibitors)

RN 209525-11-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[(1S)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209525-32-6 CAPLUS
CN 1H-Indole-2-carboxamide, N-[(1S)-1-[1-methyl-4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **209528-41-6P 209528-42-7P 209528-84-7P 209528-85-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of new heterocyclic amides as nitric oxide prodn. inhibitors)
RN 209528-41-6 CAPLUS
CN Carbamic acid, [(1S)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-42-7 CAPLUS
CN 2-Pyridineethanamine, .alpha.-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrobromide, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HBr

RN 209528-84-7 CAPLUS
CN Carbamic acid, [(1S)-1-[1-methyl-4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-85-8 CAPLUS
CN 2-Pyridineethanamine, .alpha.-[1-methyl-4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:682666 CAPLUS
DOCUMENT NUMBER: 130:13949
TITLE: An efficient synthesis of 2-[(methylamino)methyl]-4,5-dialkyl-1H-imidazoles
AUTHOR(S): Reader, Valerie A.
CORPORATE SOURCE: Department Medicinal Chemistry, Research Development Division, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA
SOURCE: Synlett (1998), (10), 1077-1078
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:13949

AB A mild and convenient synthesis of highly substituted imidazoles is described. The method is exemplified by the prepn. of 2-[(methylamino)methyl]-4,5,6,7-tetrahydro-1H-benzimidazole and 2-[(methylamino)methyl]-4,5-dimethyl-1H-imidazole.

IT **193534-58-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of [(methylamino)methyl]imidazoles)

RN 193534-58-6 CAPLUS

CN Carbamic acid, [(4,5-dimethyl-1H-imidazol-2-yl)methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT **215959-20-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of [(methylamino)methyl]imidazoles)

RN 215959-20-9 CAPLUS

CN 1H-Imidazole-2-methanamine, N,4,5-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:793862 CAPLUS
DOCUMENT NUMBER: 130:119078
TITLE: Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs
AUTHOR(S): Raevsky, Oleg A.; Schaper, Klaus-Jurgen
CORPORATE SOURCE: Laboratory of Computer-Aided Molecular Design, Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia
SOURCE: Eur. J. Med. Chem. (1998), 33(10), 799-807
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The H-bond donor and acceptor descriptors .sum.Cd and ECa, which are estd.

directly from thermodn. data of hydrogen bonding, were successfully used for the correlation with permeability and absorption data for some chems. and drugs. The evaluation of different types of permeability test systems and of different classes of compds. showed that in addn. to steric bulk effects both the H-bond donor and acceptor strength play an important role in explaining differences in permeability and absorption of neutral chem. compds. and drugs. However, because of the frequently obsd. intercorrelation between .sum.Cd and .sum.Ca, often only the more significant of them leads to a significant regression coeff. in multiple linear regression equations. In comparison with ICd and/or ECa less significant correlations are obtained with the exptl. parameter .DELTA.logP (the difference between the octanol/water partition coeff. logPOct and logP for the system alkane or cyclohexane/water) which has to be considered as a composed descriptor contg. H-bond donor as well as H-bond acceptor effects.

IT **219959-69-0 219959-71-4** 219959-72-5
219959-73-6 219959-74-7 219959-75-8
RL: BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process)
(quant. estn. of H-bond contribution to permeability and absorption processes of chems. and drugs)

RN 219959-69-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-71-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylmethylamino)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-72-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexyloxy)methyl]amino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-73-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)methyl]methylamino]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-74-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylamino)methoxy]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 219959-75-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[2-(cyclohexylamino)ethyl]-3-methylbutyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:568118 CAPLUS
DOCUMENT NUMBER: 127:248417
TITLE: Preparation of amino acid heterobicyclic amide derivatives as farnesyl transferase inhibitors
INVENTOR(S): Gordon, Thomas D.; Morgan, Barry A.
PATENT ASSIGNEE(S): Biomeasure Incorporated, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730053	A1	19970821	WO 1997-US2651	19970214
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2002013319	A1	20020131	US 1996-752546	19961120
CA 2245823	AA	19970821	CA 1997-2245823	19970214
AU 9719645	A1	19970902	AU 1997-19645	19970214
AU 716636	B2	20000302		
ZA 9701254	A	19980714	ZA 1997-1254	19970214
EP 904274	A1	19990331	EP 1997-907717	19970214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1216545	A	19990512	CN 1997-193864	19970214
JP 2001500838	T2	20010123	JP 1997-529596	19970214
TW 432066	B	20010501	TW 1997-86101769	19970214

PRIORITY APPLN. INFO.: US 1996-602438 A 19960216
US 1996-752546 A 19961120
WO 1997-US2651 W 19970214

OTHER SOURCE(S): MARPAT 127:248417

GI



I



II



III

AB Title compds. I and II [R1 = H, lower alkyl, lower alkylthio; R1R2 = CH2, CO, CMe2; R2, R3 = independently H, lower alkyl, cycloalkyl; R4 = H2, O; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6, R7 = independently H, CONHCHR13CO2R14, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6R7 = fused aryl or heterocyclyl; R8, R9 = independently H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R8, R9 = fused aryl or heterocyclyl;X = NR9, S, O; R13 = (un)substituted lower alkyl; R14 = H, lower alkyl], and pharmaceutically acceptable salts thereof are capable of inhibiting the activity of farnesyl transferase. Thus, tetrahydroimidazo[1,2a]pyrazine III, prepd. in 6 steps from Cbz-L-Nle-OH (Cbz = PhCH2O2C), BrCH2COC6H4OMe-2, BrCH2CO2Et, and Boc-L-Cys(CPh3)-OH (Boc = Me3CO2C), displayed antiproliferative activities of 6.25-12.5 .mu.M, 12.5 .mu.M, 10-30 .mu.M, and 12.5-25 .mu.M against A-427 lung carcinomas, HT-29 colon adenocarcinomas, Calu-1 lung carcinomas, and MIA PaCa pancreatic cancer cells, resp.

IT **195449-70-8P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)

RN 195449-70-8 CAPLUS

CN Propanamide, 2-amino-3-mercapto-N-[1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **195449-56-0P 195449-72-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)
RN 195449-56-0 CAPLUS
CN Propanamide, 2-amino-3-mercapto-N-methyl-N-[1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195449-72-0 CAPLUS
CN Propanamide, 3,3'-dithiobis[2-amino-N-[1-[5-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [1S-[1R*[S*[S*(R*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **195450-28-3P 195450-42-1P 195450-43-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)
RN 195450-28-3 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-42-1 CAPLUS
CN 1H-Imidazole-2-methanamine, .alpha.-butyl-N-methyl-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-43-2 CAPLUS
CN Carbamic acid, [2-[methyl[1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]-2-oxo-1-[[(triphenylmethyl)thio]methyl]ethyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:547296 CAPLUS
DOCUMENT NUMBER: 127:161822
TITLE: Benzimidazole derivatives and analogs as vitronectin receptor antagonists.
INVENTOR(S): Miller, William Henry; Bondinell, William Edward; Ku, Thomas Wen-fu; Keenan, Richard Mcculloch; Samanen, James Martin; Kwon, Chet; Ali, Fadia El-fehail; Lago, Maria A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; Miller, William Henry; Bondinell, William Edward; Ku, Thomas Wen-Fu; Keenan, Richard Mcculloch; Samanen, James Martin; Kwon, Chet; Ali, Fadia El-Fehail; Lago, Maria A.
SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724119	A1	19970710	WO 1996-US20748	19961220
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2241633	AA	19970710	CA 1996-2241633	19961220
AU 9713540	A1	19970728	AU 1997-13540	19961220
EP 869787	A1	19981014	EP 1996-945087	19961220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1209744	A	19990303	CN 1996-180113	19961220
BR 9612327	A	19990713	BR 1996-12327	19961220
JP 2000502354	T2	20000229	JP 1997-524557	19961220
ZA 9610859	A	19971024	ZA 1996-10859	19961223
NO 9803003	A	19980826	NO 1998-3003	19980626

PRIORITY APPLN. INFO.: US 1995-9366P P 19951229
WO 1996-US20748 W 19961220
OTHER SOURCE(S): MARPAT 127:161822
GI



I



II

AB A variety of imidazoles, benzimidazoles, and analogs are disclosed, e.g., I [W = XV or C6H4; X = bond, (un)substituted CH2 or CH2CH2; V = certain substituted CONH or NHCO linkages; R1, R2 = H, alkyl, aralkyl, heteroaralkyl, halo, CF3, etc.; or R1R2 forms (un)substituted 5- or 6-membered carbo- or heterocyclic ring; R3 = H, alkyl, aralkyl; A = fibrinogen receptor antagonist template]. The compds. are vitronectin receptor antagonists, useful in the treatment of osteoporosis. Invention compds. are said to inhibit binding of SKF 107260 to vitronectin receptor at 0.001 to 50 .mu.M, and to have a vitronectin receptor Ki approx. 10- to 100-fold greater than that at the fibrinogen receptor. Over 80 example compds. are given, with characterization of 59 compds. For instance, title compd. II was prepd. by amidation of 2-(aminomethyl)-4-aza-5-methylbenzimidazole di-HCl with the corresponding carboxybenzodiazepineacetate deriv., using EDC and HOBt, followed by sapon. with LiOH in aq. THF.

IT **193534-58-6P 193534-59-7P** 193534-60-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of benzimidazole derivs. and analogs as vitronectin receptor antagonists)

RN 193534-58-6 CAPLUS
CN Carbamic acid, [(4,5-dimethyl-1H-imidazol-2-yl)methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 193534-59-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N,4,5-trimethyl- (9CI) (CA INDEX NAME)



RN 193534-60-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2-acetic acid, 7-[[[(4,5-dimethyl-1H-imidazol-2-yl)methyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **193532-89-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazole derivs. and analogs as vitronectin receptor antagonists)
RN 193532-89-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2-acetic acid, 7-[[[(4,5-dimethyl-1H-imidazol-2-yl)methyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo- (9CI) (CA INDEX NAME)



L85 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:275789 CAPLUS
DOCUMENT NUMBER: 127:17634
TITLE: Research on heterocyclic compounds. XXXVII. Synthesis and antiinflammatory activity of methyl-substituted imidazo[1,2-a]pyrazine derivatives
AUTHOR(S): Rimoli, M. G.; Avallone, L.; de Caprariis, P.; Luraschi, E.; Abignente, E.; Filippelli, W.; Berrino, L.; Rossi, F.
CORPORATE SOURCE: Dipartimento di Chimica Farmaceutica e Tossicologica, Facolta di Farmacia, Universita degli Studi di Napoli Federico II, Naples, 80131, Italy
SOURCE: Eur. J. Med. Chem. (1997), 32(3), 195-203
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of methyl-substituted imidazo[1,2-a]pyrazines I (R2 = CO2H, CH2CO2H, Me, R3 = H, CO2H, R5, R6 = H, Me) bearing a carboxylic acid group on the imidazole ring were synthesized. The structures of new compds. were confirmed by 1H- and 13C-NMR spectral data; the correct assignment of carbon resonances was made by means of HETCOR and COLOC expts. Antiinflammatory, analgesic and ulcerogenic activities in vivo were evaluated and compared with those of antiinflammatory imidazopyrazines I (R2 = CH2CO2H, R3 = H, R5 = R6 = H; R2 = CO2H, R3 = H, R5 = R6 = H) and indomethacin. The inhibitory action on cyclooxygenase activity was evaluated in vitro. I (R5, R6 = H, Me) were found to be less potent than indomethacin in these assays. SARs are discussed.

IT **190381-48-7P 190381-49-8P 190381-54-5P**
190381-55-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn., cyclooxygenase inhibitory, analgesic, and antiinflammatory activity of imidazopyrazines)

RN 190381-48-7 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 6-methyl- (9CI) (CA INDEX NAME)



RN 190381-49-8 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 6-methyl- (9CI) (CA INDEX NAME)



RN 190381-54-5 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 5,6-dimethyl- (9CI) (CA INDEX NAME)



RN 190381-55-6 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 5,6-dimethyl- (9CI) (CA INDEX NAME)



IT **177842-80-7P 177842-82-9P 177842-83-0P 177842-85-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., cyclooxygenase inhibitory, analgesic, and antiinflammatory activity of imidazopyrazines)

RN 177842-80-7 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-82-9 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 5,6-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-83-0 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-85-2 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 5,6-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:467020 CAPLUS
DOCUMENT NUMBER: 125:114630
TITLE: Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
INVENTOR(S): Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616040	A1	19960530	WO 1995-US15262	19951122
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5681956	A	19971028	US 1995-401201	19950309
US 5633377	A	19970527	US 1995-462833	19950605
US 5646281	A	19970708	US 1995-461135	19950605
US 5656762	A	19970812	US 1995-461858	19950605
US 5712392	A	19980127	US 1995-464548	19950605
AU 9643689	A1	19960617	AU 1996-43689	19951122
ZA 9509910	A	19970822	ZA 1995-9910	19951122
ZA 9509911	A	19970822	ZA 1995-9911	19951122
EP 793653	A1	19970910	EP 1995-942473	19951122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ZA 9707500	A	19980223	ZA 1997-7500	19951122
JP 10502670	T2	19980310	JP 1995-517074	19951122
JP 2941950	B2	19990830		
BR 9509760	A	19980630	BR 1995-9760	19951122
US 6069251	A	20000530	US 1997-859861	19970521

PRIORITY APPLN. INFO.:
US 1994-344154 A2 19941123
US 1994-344552 A2 19941123
US 1995-401201 A2 19950309
US 1990-635256 A2 19901228
US 1993-81317 A2 19931108
US 1994-313435 A2 19940927
US 1995-462833 A1 19950605
WO 1995-US15262 W 19951122

OTHER SOURCE(S): MARPAT 125:114630
GI



AB Disclosed are compds. (I), wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are org. or inorg. substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are org. or inorg. substituents; and the pharmaceutically acceptable addn. salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-phenyl-4(5)-[(4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was prepd. and was shown to bind to the dopamine D4 receptor site (Ki = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).

IT **179332-49-1P 179333-51-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)

RN 179332-49-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 179333-51-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L35 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:462297 CAPLUS
DOCUMENT NUMBER: 125:143312
TITLE: Preparation of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compounds as endothelin antagonists.

Searched by Barb O'Bryen STIC 308-4291

INVENTOR(S): Von Geldern, Thomas; Kester, Jeffrey A.; Tasker, Andrew S.; Sorensen, Brian K.; Rosenberg, Saul H.; Hutchins, Charles W.; Winn, Martin
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611927	A1	19960425	WO 1995-US13373	19951010

W: CA, JP, MX
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1994-322114 19941012
US 1995-442124 19950530

OTHER SOURCE(S): MARPAT 125:143312
GI



I



II

AB Title compds. [I; X = imino, O, S; Q = O, (substituted) methylene; R1 = alkyl, cycloalkyl, aralkyl aralkenyl, aryloxy, amino, spirocarbocyclyl, spiroheterocyclyl, etc.; E = (substituted) alkyl; G = H, alkyl; Ar = aryl, bicyclic aryl, bicyclic heteroaryl; Y = H, (substituted) alkyl, cycloalkyl, aryl, aralkyl; Z = acyl, cyano, OH, tetrazolyl, OH, alkoxy, sulfonamido, specified heterocyclyl, etc.], were prepd. Thus, title compd. (II), prepd. by soln. phase couplings, at 1 .mu.M inhibited [125I]ET-1 binding to endothelin A receptors by 81.2%.

IT **172922-38-2P 172922-39-3P 179169-17-6P**
179169-18-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 172922-38-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-39-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2R)-2-[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-17-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylmethylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-18-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[(methylphenylamino)carbonyl]oxy]-1-oxopentyl]amino]ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168470-61-9P 168470-62-0P 179169-34-7P 179169-36-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of [(acylamino)(indolyl)ethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 168470-61-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-62-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-34-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179169-36-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-,

phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:239751 CAPLUS
DOCUMENT NUMBER: 124:289584
TITLE: Preparation of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists
INVENTOR(S): Ali, Fadia; Bondinell, William; Huffman, William Francis; Lago, M. Amparo; Keenan, Richard Mcculloch; Kwon, Chet; Miller, William Henry; Nguyen, Thomas; Takata, Dennis T.
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600730	A1	19960111	WO 1995-US8306	19950629
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9530010	A1	19960125	AU 1995-30010	19950629
AU 702661	B2	19990225		
EP 767792	A1	19970416	EP 1995-926152	19950629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1156995	A	19970813	CN 1995-194853	19950629
HU 76344	A2	19970828	HU 1996-3525	19950629
BR 9508178	A	19971118	BR 1995-8178	19950629
JP 10504808	T2	19980512	JP 1995-503462	19950629
US 5977101	A	19991102	US 1996-505171	19961220
NO 9605608	A	19970227	NO 1996-5608	19961227
PRIORITY APPLN. INFO.:			US 1994-267695	19940629
			US 1995-428933	19950425
			WO 1995-US8306	19950629

OTHER SOURCE(S): MARPAT 124:289584
GI



I



II

AB Title compds. [e.g., I; A = fibrinogen receptor antagonist template (sic); G = Nh, O, S, etc.; R2,R3 = H, halo, alkyl, etc.; R2R3 = atoms to form a ring; W = CHR1UCHR1V, VZ; R1 = H, (un)substituted alkyl; U,V = bond, CO, O, CH:CH, etc.; Z = N-attached pyrrolidine- or piperidine-di-yl] were prepd. Thus, Me 7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was amidated by 2-aminomethylbenzimidazole to give, after sapon., title compd. II. Title compds. inhibit vitronectin binding to SK&F 107260 in the concn. range of about 0.001 to 50.mu.M (sic).

IT **175529-80-3P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)

RN 175529-80-3 CAPLUS

CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT **175531-38-1**
RL: RCT (Reactant)
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)

RN 175531-38-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



IT **175531-07-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)

RN 175531-07-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]-, methyl ester (9CI)

(CA INDEX NAME)



L35 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:73845 CAPLUS
DOCUMENT NUMBER: 124:127005
TITLE: Azole Endothelin Antagonists. 3. Using .DELTA. log P as a Tool To Improve Absorption
AUTHOR(S): von Geldern, Thomas W.; Hoffman, Daniel J.; Kester, Jeffrey A.; Nellans, Hugh N.; Dayton, Brian D.; Calzadilla, Samuel V.; Marsh, Kennan C.; Hernandez, Lisa; Chiou, William; et al.
CORPORATE SOURCE: Pharmaceutical Products Research Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
SOURCE: J. Med. Chem. (1996), 39(4), 982-91
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The oral absorption profile of a family of azole-based ETA-selective antagonists has been improved through a rational series of structural modifications which were suggested by anal. of the physicochem. parameter .DELTA. log P. Comparison of urea I with a series of well-absorbed compds. using .DELTA. log P anal. suggested that I has an excess capacity for forming hydrogen bonds with solvent. A series of urea modifications were explored as a means of reducing H-bonding capacity while maintaining affinity for the ETA-receptor. The correlation between .DELTA. log P values and absorption in an intraduodenal (id) bioavailability model was good; this strategy uncovered replacements for each of the urea NH groups which simultaneously improve both potency and drug absorption. A combination of these optimized modifications produces a carbamate which is a highly-selective ETA antagonist with a potency/bioavailability profile

consistent with an oral route of administration.

IT **168468-58-4P 168468-74-4P 168468-80-2P 168468-84-6P 172922-37-1P 172922-38-2P 172922-39-3P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azole endothelin antagonists: using .DELTA. log P as a tool to improve absorption)

RN 168468-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-74-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylmethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-80-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexyloxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-84-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-37-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-38-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]oxy]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-39-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2R)-2-[2-(cyclohexylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **172922-29-1P 172922-45-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(azole endothelin antagonists: using .DELTA. log P as a tool to improve absorption)
RN 172922-29-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172922-45-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(1,1-dimethylethoxy)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:73848 CAPLUS
DOCUMENT NUMBER: 124:193276
TITLE: Azole Endothelin Antagonists. 2. Structure-Activity Studies
AUTHOR(S): von Geldern, Thomas W.; Kester, Jeffrey A.; Bal, Radhika; Wu-Wong, Jinshyun R.; Chiou, William; Dixon, Douglas B.; Opgenorth, Terry J.
CORPORATE SOURCE: Pharmaceutical Products Research, Abbott Laboratories, Abbott Park, IL, 60064, USA
SOURCE: J. Med. Chem. (1996), 39(4), 968-81
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:193276

AB Structure-activity studies have been performed to improve the potency of a novel series of azole-based endothelin-A (ETA) selective antagonists. Modifications of the hydrophobic group on the terminal urea produced substantial effects on receptor affinity; in particular, the choice of cyclohexyl- or arylureas led to substantial improvements in activity. Conformational restriction of these groups provides an addnl. benefit. N-Methylation of the indole moiety which is part of the heterocyclic dipeptide surrogate also improves potency. The effects of these two modifications appear to be synergistic, with the best of the resultant doubly modified analogs exhibiting an 80-200-fold improvement over the original leads.

IT **168470-58-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of azole peptide endothelin antagonists in relation to structure)

RN 168470-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168468-13-1P 168468-58-4P 168468-60-8P 168468-70-0P 168468-72-2P 168468-82-4P 174063-59-3P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(prepn. of azole peptide endothelin antagonists in relation to structure)

RN 168468-13-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-60-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 168468-70-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclopentylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-72-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cycloheptylamino)carbonyl]amin

o]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-82-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[(phenylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-59-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1.alpha.[R*(S*)],3.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168468-15-3P 168468-30-2P 168468-31-3P**

168468-33-5P 168468-37-9P 168468-41-5P
168468-62-0P 168468-68-6P 168468-75-5P
173962-20-4P 174063-51-5P 174063-52-6P
174063-56-0P 174063-57-1P 174063-58-2P
174063-60-6P
RL: BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(prepn. of azole peptide endothelin antagonists in relation to structure)

RN 168468-15-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-30-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-1,5-dimethyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-31-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-1-(phenylmethyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-33-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-37-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)sulfonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-41-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-

[[[(phenylmethyl)amino]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-62-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [1(1R)-[1.alpha.[1R*(S*)],4.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-68-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(4-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 168468-75-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-ethyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 173962-20-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(diethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-51-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1.alpha.[S*(R*)],2.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-52-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1.alpha.[R*(S*)],3.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-56-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1.alpha.[S*(R*)],2.beta.]]- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 174063-57-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1.alpha.[R*(S*)],2.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-58-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1S-[1.alpha.[R*(S*)],2.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174063-60-6 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, [1R-[1.alpha.[S*(R*)],3.beta.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168470-54-0**
RL: RCT (Reactant)
(reactant; prepn. of azole peptide endothelin antagonists in relation to structure)

RN 168470-54-0 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:73847 CAPLUS
DOCUMENT NUMBER: 124:164291
TITLE: Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure-Activity Profile
AUTHOR(S): von Geldern, Thomas W.; Hutchins, Charles; Kester, Jeffrey A.; Wu-Wong, Jinshyun R.; Chiou, William; Dixon, Douglas B.; Opgenorth, Terry J.
CORPORATE SOURCE: Pharmaceutical Products Research Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
SOURCE: J. Med. Chem. (1996), 39(4), 957-67
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:164291

AB The pseudotetrapeptide FR-139317 is a potent and highly selective

antagonist of the endothelin-A (ETA) receptor; however, its peptidic nature leads to poor oral absorption characteristics which make it an unlikely drug candidate. To improve these properties, the authors have replaced a portion of the amide bond framework of FR-139317 with a heterocyclic surrogate. The resultant analogs are also ETA-selective antagonists, but show a structure-activity profile substantially different from that of the peptidic series, particularly with regard to the requirements for the side chain group that has been incorporated into the heterocycle. The nature of the heterocycle itself also has profound effects on the activity of the compds. Both of these surprising results can be rationalized through examn. of a 3D model of ET ligand-receptor binding that has previously been developed in the authors labs.

IT **168470-54-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (intermediate; prepn. of azole peptide endothelin antagonists in relation to receptor model explaining unusual structure-activity profile)

RN 168470-54-0 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168468-13-1P 168468-20-0P 168468-22-2P 168468-24-4P**

RL: BPR (Biological process); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (prepn. of azole peptide endothelin antagonists in relation to receptor model explaining unusual structure-activity profile)

RN 168468-13-1 CAPLUS

CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-20-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-22-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-propyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-24-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-

(1-methylethyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:289688 CAPLUS
DOCUMENT NUMBER: 125:33072
TITLE: 1H and 13C NMR spectra of imidazo[1,2-a]pyrazines
AUTHOR(S): Avallone, Lucia; De Caprariis, Paolo; Galeone, Aldo; Rimoli, Maria Grazia
CORPORATE SOURCE: Dipartimento di Chimica Farmaceutica, Naples, I-80131, Italy
SOURCE: Magn. Reson. Chem. (1996), 34(5), 409-414
CODEN: MRCHEG; ISSN: 0749-1581
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB 1H and 13C NMR spectra data for several imidazo[1,2-a]pyrazines(e.g., I and II) were detd. The chem. shift assignments were based on HETCOR and COLOC spectra for some model compds.

IT **177842-80-7 177842-82-9 177842-83-0 177842-85-2**
RL: PRP (Properties)
(1H and 13C NMR spectra of imidazo[1,2-a]pyrazines)

RN 177842-80-7 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-82-9 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 5,6-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-83-0 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 6-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 177842-85-2 CAPLUS
CN Imidazo[1,2-a]pyrazine-2-acetic acid, 5,6-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1995:828329 CAPLUS
DOCUMENT NUMBER:	123:257412
TITLE:	Preparation of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates and related compounds as endothelin antagonists.
INVENTOR(S):	Vongeldern, Thomas W.; Kester, Jeffrey A.; Rosenberg, Saul H.; Winn, Martin; Hutchins, Charles W.
PATENT ASSIGNEE(S):	Abbott Laboratories, USA
SOURCE:	PCT Int. Appl., 193 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9508550	A1	19950330	WO 1994-US10049	19940907

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1993-126822 19930924
US 1994-295441 19940829

OTHER SOURCE(S): MARPAT 123:257412

GI



I



Q1=



Q2=



Q3=



Q4=



Q5=

AB Title compds. [I; m = 0-2; X = NR2, O, S; R2 = H, alkyl, aralkyl, heterocyclylalkyl; Q = R1ANB, Q1; A = CO, SO2; R1 = alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, aryl, alkoxy, aralkoxy, cycloalkylamino, heterocyclyl, heterocyclylamino, spirocarbocyclyl, spiroheterocyclyl, etc.; B = H, alkyl; R20 = alkyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, spirocarbocyclyl, spiroheterocylcyl; r = 2-4; E = (substituted) alkyl; G = H, alkyl; Ar = bicyclic aryl, heteroaryl; Y, Z = H, (substituted) alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, (CH2)nCOW, (CH2)nV, etc.; n = 0-2; V = Q2-Q5, tetrazolyl, PO3H2, cyano, etc.; W = OR10; R10 = H, protecting group, amino, alkylamino, hydroxyamino, .alpha.-amino acid residue, etc.; with a proviso], were prepd. Thus, 2[(1R)-1-[N-(1-oxa-4-azaspiro[5.4]decane-4-carbonyl)leucylamino]-2-(1-methylindol-3-yl)ethyl]-5-methyloxazole-4-carboxylic acid (soln. phase prepn. given) at 1 .mu.M gave 98.4% inhibition of 125I-endothelin-1 binding to cell membranes.

IT **168468-14-2P 168468-15-3P 168468-21-1P**
168468-23-3P 168468-25-5P 168468-28-8P
168468-29-9P 168468-30-2P 168468-32-4P
168468-34-6P 168468-36-8P 168468-38-0P
168468-40-4P 168468-41-5P 168468-43-7P
168468-45-9P 168468-47-1P 168468-49-3P
168468-51-7P 168468-53-9P 168468-55-1P

168468-57-3P 168468-59-5P 168468-61-9P
168468-63-1P 168468-65-3P 168468-67-5P
168468-69-7P 168468-71-1P 168468-73-3P
168468-74-4P 168468-75-5P 168468-77-7P
168468-78-8P 168468-79-9P 168468-81-3P
168468-83-5P 168468-84-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates and related compds. as endothelin antagonists)

RN 168468-14-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-13-1
CMF C28 H38 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-15-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-21-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-ethyl-2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-20-0
CMF C29 H40 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-23-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-propyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-22-2
CMF C30 H42 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-25-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-(1-methylethyl)-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-24-4
CMF C30 H42 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-28-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-27-7
CMF C30 H42 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-29-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-30-2 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-1,5-dimethyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-32-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-1-(phenylmethyl)-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-31-3
CMF C35 H44 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-34-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-33-5
CMF C28 H38 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-36-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[2-[[[4-(methoxymethoxy)-1-piperidinyl]carbonyl]amino]-4-methyl-1-oxopentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-35-7
CMF C29 H40 N6 O6
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-38-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)sulfonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 168468-37-9
CMF C27 H38 N6 O5 S
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-40-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-39-1
CMF C26 H35 N5 O5
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-41-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[(phenylmethyl)amino]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-43-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[(phenylacetyl)amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-42-6
CMF C29 H33 N5 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-45-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-44-8
CMF C29 H39 N5 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-47-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cycloheptylcarbonyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-46-0
CMF C29 H39 N5 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-49-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-48-2
CMF C30 H39 N5 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-51-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[2-[[(4-methoxyphenyl)acetyl]amino]-4-methyl-1-oxopentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-50-6
CMF C30 H35 N5 O5
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-53-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(3,3-dimethyl-1-oxobutyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-52-8
CMF C27 H37 N5 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-55-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[(1-oxo-2-propylpentyl)amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-54-0
CMF C29 H41 N5 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-57-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[(3-pyridinylcarbonyl)amino]pentyl]amino]ethyl]-5-methyl-, [R-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-56-2
CMF C27 H30 N6 O4
CDES 1:R2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-59-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-58-4
CMF C29 H40 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-61-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-60-8
CMF C30 H40 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-63-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[[(4-hydroxycyclohexyl)amino]carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [1(1R)-[1.alpha.[1R*(S*)],4.beta.]]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 168468-62-0
CMF C29 H40 N6 O5
CDES *

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-65-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(2-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-64-2
CMF C30 H42 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-67-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(3-methylcyclohexyl)amino]carbonyl]amino]-1-

oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-66-4
CMF C30 H42 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-69-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-2-[[[(4-methylcyclohexyl)amino]carbonyl]amino]-1-oxopentyl]amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-68-6
CMF C30 H42 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-71-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclopentylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-70-0
CMF C28 H38 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-73-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cycloheptylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-72-2
CMF C30 H42 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-74-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylmethylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-75-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-ethyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-77-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-3-(1H-indol-3-yl)propyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-78-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]methylamino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-79-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168468-81-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexyloxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-80-2
CMF C29 H39 N5 O5
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-83-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 5-methyl-2-[2-(1-methyl-1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[(phenylamino)carbonyl]amino]pentyl]amino]ethyl]-, [S-(R*,S*)]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 168468-82-4
CMF C29 H34 N6 O4
CDES 1:S2:R*,S*

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 168468-84-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[(1R)-1-[[(2S)-2-[[(cyclohexylamino)carbonyl]methylamino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **168468-27-7P 168470-54-0P 168470-55-1P**
168470-58-4P 168470-59-5P 168470-60-8P
168470-61-9P 168470-62-0P 168470-63-1P
168470-65-3P 168470-66-4P 168470-67-5P
168470-70-0P 168470-71-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of [(aminocarbonylleucylamino)indolylethyl]azolecarboxylates and related compds. as endothelin antagonists)
RN 168468-27-7 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-54-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[(phenylmethoxy)carbonyl]amino]ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-55-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-amino-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-58-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-59-5 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[2-(1H-indol-3-yl)-1-[[4-methyl-1-oxo-2-[[[(phenylmethyl)amino]carbonyl]amino]pentyl]amino]ethyl]-5-methyl-, ethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-60-8 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[(cyclohexylacetyl)amino]-4-methyl-1-oxopentyl]amino]-2-(1H-indol-3-yl)ethyl]-5-methyl-, ethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-61-9 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-62-0 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-63-1 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[2-[[(cyclohexylamino)carbonyl]amino]-4-methyl-1-oxopentyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-5-methyl-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-65-3 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-(1-methyl-1H-indol-3-yl)ethyl]-, ethyl ester, (R)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 168470-66-4 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-[1-amino-2-(1-methyl-1H-indol-3-yl)ethyl]-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 168470-67-5 CAPLUS
CN 1H-Imidazole-midazoles, e.g. I, and 2-substituted 5-methyl-4-phenylcarbamoyl-1H-imidazoles were synthesized from 5-acylamino-6-methyluracils, e.g. II, and 5-acylamino-6-methyl-3-phenylpyrimidin-4(3H)ones by treatment with sodium hydroxide in ethanol. In the case of 5-acylaminopyrimidiones which possess an olefinic group in the acylamino group, 2-ethoxyethyl (or 2-ethoxypropyl)-5-methyl-4-phenylcarbamoyl-1H-imidazoles were prepd. as major products and the corresponding 2-alkenyl-1H-imidazoles were only minor products. Compds. which contain an aryl function in their acylamino group gave glycine anilides as byproducts.
IT **138711-51-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 138711-51-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-[(dimethylamino)methyl]-5-methyl-N-phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:167468 CAPLUS
DOCUMENT NUMBER: 108:167468
TITLE: Preparation of (heterocyclylalkyl)imidazoles as dopamine .beta.-hydroxylase inhibitors, and their use as antihypertensives.
INVENTOR(S): Matthews, Donald P.; McCarthy, James R.; Whitten, Jeffrey P.; Broersma, Robert J., Jr.
PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 244803	A2	19871111	EP 1987-106440	19870504
EP 244803	A3	19910116		
EP 244803	B1	19941026		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01100160	A2	19890418	JP 1987-106478	19870501
JP 2581556	B2	19970212		
IL 82401	A1	19930131	IL 1987-82401	19870501
AU 8772463	A1	19871112	AU 1987-72463	19870504
AU 596410	B2	19900503		
ZA 8703176	A	19871230	ZA 1987-3176	19870504
ES 2065881	T3	19950301	ES 1987-106440	19870504
DK 8702291	A	19871107	DK 1987-2291	19870505
FI 8701981	A	19871107	FI 1987-1981	19870505
NO 8701861	A	19871109	NO 1987-1861	19870505
HU 44029	A2	19880128	HU 1987-2013	19870505
HU 198479	B	19891030		
CN 87103323	A	19880203	CN 1987-103323	19870505
CA 1334199	A1	19950131	CA 1987-536384	19870505
US 5057613	A	19911015	US 1987-114168	19871027
US 4810800	A	19890307	US 1988-188661	19880429
US 5189052	A	19930223	US 1989-453648	19891220

PRIORITY APPLN. INFO.: US 1986-860263 19860506
US 1987-114166 19871027
US 1987-114168 19871027

OTHER SOURCE(S): CASREACT 108:167468
GI



AB (Heterocyclylalkyl)imidazoles [I; n = 0-4; X = H, cyano, Cl, Br, alkyl, (substituted) Ph, CH2Ph; Y = H, aminomethyl, amido, .alpha.-ketoacid or ester, thioamido, amidino, aminoethylthio, SH; when Y = SH or aminoethylthio, X = H; Het = (alkyl- or halo-substituted) thienyl, furyl, pyridyl, pyrimidinyl, pyrazolyl, pyrrolyl, thiazolyl, imidazol-2-yl) and

their 2-thione tautomers, which inhibit dopamine .beta.-hydroxylase and are useful as antihypertensives, are prepd. Thiophene-2-carboxaldehyde was treated with aminoacetaldehyde di-Et acetal and the resulting imine was redced and cyclized to give the imidazole thione II. At 50 mg/kg i.p., II-treated spontaneously hypertensive rats had av. heart dopamine levels of 0.066 .+-. 0.005 compared to 0.024 .+-. .003 .mu.g/g heart tissue, 3 h after dosage. The blood pressure in the treated rats decreased 18%.

IT **113825-18-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclocondensation of, with thiocyanate)

RN 113825-18-6 CAPLUS

CN 1H-Imidazole-2-methanamine, N-(2,2-diethoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1981:192292 CAPLUS
DOCUMENT NUMBER: 94:192292
TITLE: Synthesis of aminoalkyl-substituted imidazo[1,2-a]- and imidazo[1,5-a]benzodiazepines
AUTHOR(S): Gall, Martin; Kamdar, Bharat V.
CORPORATE SOURCE: CNS Dis. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: J. Org. Chem. (1981), 46(8), 1575-85
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Imidazo[1,2-a]benzodiazepines were prepd. in good yields from benzodiazepinethiones and the amino ketals I (R = OH, NMe2, phthalimido, N3, Br, CH2NMe2, CH2OH, phthalimidomethyl). The 1-(hydroxymethyl)- and 1-unsubstituted-imidazo[1,2-a][1,4]benzodiazepines were easily transformed into 1-[(dimethylamino)methyl]imidazo[1,5-a][1,4]benzodiazepines by ring-opening, reductive methylation, and hydroxymethylation of the 1-unsubstituted starting material under Eschweiler-Clarke reaction conditions, followed by transformation of the hydroxyl group to a phthalimide and hydrazinolysis-cyclization to the products. I were prepd. from phthalimidoacetone.

IT **76900-23-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 76900-23-7 CAPLUS

CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4-methyl-1H-imidazol-1-yl]phenyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)



L35 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1975:606276 CAPLUS
DOCUMENT NUMBER: 83:206276
TITLE: Imidazoles
INVENTOR(S): Yokobe, Tetsuo; Arai, Tomio; Abe, Masao
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50096569	A2	19750731	JP 1974-3003	19731227
JP 57058342	B4	19821209		

GI For diagram(s), see printed CA Issue.
AB Nitrophenylimidazoles (I, R = NO2, R1, R2 = alkyl, R3, R4 = H, alkyl, R5, R6 = H, halogen useful as peripheral vasodilators (no data), were prepd. by nitrating I (R = H). Thus, 3.1 g 1-(2-benzoylphenyl)-2-(dimethylaminomethyl)imidazole was nitrated with NaNO3-H2SO4 to give 2.4 g 1-(2-benzoyl-4-nitrophenyl)-2-(dimethylaminomethyl)imidazole.
IT **57339-42-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 57339-42-1 CAPLUS
CN Methanone, [2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]-5-nitrophenyl]phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1976:105590 CAPLUS
DOCUMENT NUMBER: 84:105590
TITLE: Imidazole derivatives
INVENTOR(S): Yokobe, Tetsuo; Arai, Tomio; Abe, Masao
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50095264	A2	19750729	JP 1974-3839	19731226
JP 57053342	B4	19821112		

GI For diagram(s), see printed CA Issue.

AB Oxidn. of imidazoles (I, Z = lower alkylene; X = CH, N; R = H, halo, NO2, MeSO2; R1, R2 = alkyl, cycloalkyl, aryl, aralkyl, or NR1R2 = heterocycle; R3, R4 = H, alkyl; R5, R6 = H, halo) gave II. Thus, 4.0 g I (Z = CH2, X = CH, CZ1 = CH2, R = 4-NO2, R1 = R2 = Et, R3 = R4 = R6 = H, R5 = 2-Cl) was oxidized with CrO3-dild. H2SO4-AcOH to give 3.2 g (Z = CH2, X = CH, R = NO2, R1 = R2 = Et, R3 = R4 = R6 = H, R5 = 2-Cl) fumarate. Among 24 compds. similarly prepd. were II [Z, X, R, R1, R2 (or NR1R2), R3-6 given] CH2, CH, H, morpholino, H, H, 4-Cl, H; CH2, CH, Cl, Me, Me, Me, Me, H, H; (CH2)2, CH, NO2, Me, Me, H, H, 2-Cl, H; CH2, N, NO2, Me, Me, H, H, H, H.

IT **58487-32-4**
RL: RCT (Reactant)
(oxidn. of)

RN 58487-32-4 CAPLUS

CN Benzenemethanol, 5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]-.alpha.-phenyl- (9CI) (CA INDEX NAME)



IT **54534-29-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 54534-29-1 CAPLUS

CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1975:557696 CAPLUS
DOCUMENT NUMBER: 83:157696
TITLE: Antihistaminic activities of certain 4-phenylimidazoles
AUTHOR(S): Morgenstern, R.; Bechmann, K.
CORPORATE SOURCE: Inst. Pharmakol. Toxikol., Humboldt-Univ., Berlin, E. Ger.
SOURCE: Pharmazie (1975), 30(2), 103-5
CODEN: PHARAT
DOCUMENT TYPE: Journal
LANGUAGE: German

GI For diagram(s), see printed CA Issue.

AB All 40 4-phenylimidazoles (I) tested for antihistaminic activity on guinea pig ileum were effective and inhibited histamine-induced contractions competitively and noncompetitively dependent on the dose. Some compds. at concns. below antagonistic values induced contractions themselves. The influence of substituents at C-4, C-2, N-1, or C-5 on antihistaminic activity was discussed.

IT **48167-31-3 48184-54-9 54887-81-9 54887-82-0 54887-83-1 54887-85-3 54887-86-4**
RL: BIOL (Biological study)
(antihistaminic)

RN 48167-31-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 48184-54-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N,1-trimethyl- (9CI) (CA INDEX NAME)



RN 54887-81-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 54887-82-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 54887-83-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N,1-trimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 54887-85-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)



RN 54887-86-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N-diethyl-5-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1975:410180 CAPLUS
DOCUMENT NUMBER: 83:10180
TITLE: Imidazole derivatives
INVENTOR(S): Nakanishi, Michio; Yokobe, Tetsuo; Arai, Tomio; Abe, Masao
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.
SOURCE: Japan. Kokai, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49134677	A2	19741225	JP 1973-52232	19730510
JP 57061739	B4	19821225		
US 3927011	A	19751216	US 1974-432115	19740109

PRIORITY APPLN. INFO.: JP 1973-52232 19730510
JP 1973-53826 19730514
JP 1973-68116 19730616
JP 1973-76945 19730707

GI For diagram(s), see printed CA Issue.

AB Imidazoles I (X = CH or N; R1,R2 = H, halogen, or lower alkyl; R3 = H, halogen, or NO2; R4,R5 = H or halogen) were prepd. by treating II with HCO2H and HCHO in an acidic medium. I were muscle relaxants, anticonvulsants, analgesics, sedatives, and anesthetic potentiators. Thus, 5 g 8-nitro-6-phenyl-4H-imidazo[1,2-a][1,4]benzodiazepine was refluxed 7 hr with 20 ml 37% HCHO and 10 ml 90% HCO2H to give 4.9 g 1-(2-benzoyl-4-nitrophenyl)-2-dimethylaminomethylimidazole. Among 12 more I similarly prepd. were: 1-(2-benzoylphenyl)-2-dimethylaminomethylimidazole, 1-[2-(2-fluorobenzoyl)-4-nitrophenyl]-2-dimethylaminomethylimidazole, 1-[2-(2-chlorobenzoyl)-4-nitrophenyl]-2-dimethylaminomethylimidazole, and 1-[2-(4-bromobenzoyl)-4-nitrophenyl]-2-dimethylaminomethylimidazole.

IT **54534-29-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and analgesic, anticonvulsant, and sedative activities of)

RN 54534-29-1 CAPLUS

CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1974:536187 CAPLUS
DOCUMENT NUMBER: 81:136187
TITLE: 1-Phenylimidazole derivatives
INVENTOR(S): Nakanishi, Michio; Yokobe, Tetsuo; Arai, Tomio; Abe, Masao
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd.
SOURCE: Ger. Offen., 33 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2403416	A1	19740725	DE 1974-2403416	19740124
DE 2403416	C2	19820304		

JP 49095970	A2	19740911	JP 1973-10462	19730124
JP 57061737	B4	19821225		
JP 49116065	A2	19741106	JP 1973-31153	19730316
JP 57061738	B4	19821225		
JP 49117466	A2	19741109	JP 1973-32157	19730320
JP 49135971	A2	19741227	JP 1973-53826	19730514
JP 50014679	A2	19750215	JP 1973-68116	19730616
JP 55037558	B4	19800929		
JP 50025564	A2	19750318	JP 1973-76945	19730707
JP 58002941	B4	19830119		

PRIORITY APPLN. INFO.:

JP 1973-10462	19730124
JP 1973-31153	19730316
JP 1973-32157	19730320
JP 1973-53826	19730514
JP 1973-68116	19730616
JP 1973-76945	19730707

GI For diagram(s), see printed CA Issue.

AB Sixty-four phenylimidazoles I (R = e.g. Me, Et, or Ph; R1 = e.g. Me, Et, or H or NRR1 = e.g. morpholino or 4-methyl-1-piperazinyl; R2 = e.g. NO2 or Cl; R3 = e.g. Ph, 2-ClC6H4, 2-FC6H4, or 2-pyridyl) and (or) their salts, e.g. fumarates, useful as agents for increasing the blood supply of the brain, were prepd. by reaction of the (aminomethyl)imidazoles with 5,2-R2ClC6H3COR3 in the presence of NaH in DMF.

IT **54534-29-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 54534-29-1 CAPLUS

CN Methanone, [5-chloro-2-[2-[(dimethylamino)methyl]-4,5-dimethyl-1H-imidazol-1-yl]phenyl]phenyl- (9CI) (CA INDEX NAME)



L35 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1973:136289 CAPLUS

DOCUMENT NUMBER: 78:136289

TITLE: Imidazole derivatives

INVENTOR(S): Bornowski, Heinz; Herzig, Guenter

SOURCE: Fr. Demande, 14 pp.
CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2132632	A1	19721124	FR 1972-4864	19720214
FR 2132632	B1	19770415		
CH 572041	A	19760130	CH 1972-4956	19720405
SU 450805	T	19741125	SU 1972-1768897	19720406

PRIORITY APPLN. INFO.: DD 1971-154266 19710407

AB The imidazoles I (R = morpholino, piperidino, Me2N, Et2N; R1 = H, 3,4-(MeO)2, p-MeO, p-HO, m-NO2, p-Br; R2 = H, Me, Pr; R3 = H, Me) and their acid salts were prepd. by Mannich reaction of the corresponding phenylimidazoles. Thus, 4-(3-4-dimethoxyphenyl)-5-propylimidazole was heated at 100.degree. with HCHO and morpholine in HOAc to give 69% I (R = morpholino, R1 = 3,4-(MeO)2, R2 = Pr, R3 = H), isolated as the di-HCl salt.

IT **41053-81-0P 41053-82-1P 41053-83-2P**
41053-92-3P 41053-93-4P 41054-00-6P
41054-01-7P 41054-07-3P 41054-08-4P
41054-10-8P 41054-11-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 41053-81-0 CAPLUS

CN 1H-Imidazole-2-methanamine, N,N-dimethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41053-82-1 CAPLUS

CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41053-83-2 CAPLUS

CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 48167-31-3
CMF C14 H19 N3



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 41053-92-3 CAPLUS
RN 41053-93-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41054-00-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N,5-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41054-01-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N-diethyl-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41054-07-3 CAPLUS
CN Phenol, 4-[2-[(dimethylamino)methyl]-1-methyl-1H-imidazol-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41054-08-4 CAPLUS
CN Phenol, 4-[2-[(dimethylamino)methyl]-1-methyl-1H-imidazol-4-yl]-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 48167-13-1
CMF C13 H17 N3 O



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 41054-10-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N,1-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 41054-11-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dimethoxyphenyl)-N,N,1-trimethyl-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 48184-54-9
CMF C15 H21 N3 O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L35 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1971:53642 CAPLUS
DOCUMENT NUMBER: 74:53642
TITLE: Synthesis of imidazole derivatives
AUTHOR(S): Towliati, Hossein
CORPORATE SOURCE: Pharm.-Chem. Inst., Univ. Karlsruhe, Karlsruhe, Ger.
SOURCE: Chem. Ber. (1970), 103(12), 3952-3
CODEN: CHBEAM
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Reaction of 1 mole glyoxal dioxime with 2 moles isonitrosopropiophenone

(I) gave 1-hydroxy-4-methyl-2-(hydroxyiminomethyl)-5-phenylimidazole 3-oxide (II). The fact that only 1 mole I was consumed was explained by the assumption that the dioxime existed under the above conditions in the syn, anti configuration and that only the syn form participated in the reaction.

IT **30450-50-1P 30450-52-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 30450-50-1 CAPLUS
CN Imidazole, 2-(aminomethyl)-4-methyl-5-phenyl-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 30450-52-3 CAPLUS
CN Imidazole, 2-(aminomethyl)-4-methyl-5-phenyl- (8CI) (CA INDEX NAME)



L35 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1970:121434 CAPLUS
DOCUMENT NUMBER:	72:121434
TITLE:	Mannich reaction of imidazoles
AUTHOR(S):	Stocker, Fred B.; Kurtz, James L.; Gilman, Byron L.; Forsyth, David A.
CORPORATE SOURCE:	Dep. of Chem., Macalester Coll., St. Paul, Minn., USA
SOURCE:	J. Org. Chem. (1970), 35(4), 883-7 CODEN: JOCEAH
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB In the Mannich reaction of imidazoles, the ring is reactive at the four possible sites, the 1, 2, 4, and 5 positions. Only N-substituted imidazole Mannich bases are formed in acidic media. Both N-substituted and C-substituted products are formed in basic media. The process of N substitution is reversible in base, while C substitutio n is irreversible, resulting in the accumulation of C-substituted prod- -ucts over time in basic media. The 1 position is most reactive, with the 4 and 5 positions more reactive than the 2 position. Imidazoles having substituents at the 1 position do not react in the Mann ich reaction. A mechanism is proposed which explains the behavior of the imidazole ring in the Mannich reaction.

IT **23230-50-4P 23263-75-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 23230-50-4 CAPLUS

CN Imidazole, 2-[(diethylamino)methyl]-4,5-dimethyl- (8CI) (CA INDEX NAME)



RN 23263-75-4 CAPLUS
CN Imidazole, 2-[(diethylamino)methyl]-4,5-dimethyl-, dihydrochloride (8CI) (CA INDEX NAME)



●2 , HCl

FILE 'CAOLD' ENTERED AT 15:36:32 ON 27 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L1              STR
L2  (    332465)SEA FILE=REGISTRY ABB=ON  (16.195.22 OR 16.195.24 OR 333.871)/R
                ID
L3         4066 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L9              STR
L14             STR
L16             STR
L20          25 SEA FILE=REGISTRY SUB=L3 SSS FUL L9
L27        1828 SEA FILE=REGISTRY SUB=L3 SSS FUL (L14 AND L16)
L32           0 SEA FILE=CAOLD ABB=ON L20 OR L27
```

this page
intentionally blank

IS NOT A RECOGNIZED COMMAND

=> fil capl; s l28 and l25
FILE 'CAPLUS' ENTERED AT 15:37:22 ON 27 FEB 2002

FILE COVERS 1907 - 27 Feb 2002 VOL 136 ISS 9
FILE LAST UPDATED: 26 Feb 2002 (20020226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

L36 2 L28 AND L25 inventors' work

=> d ibib abs fhit l36 1-2; fil hom
'FHIT' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
=> d ibib abs fhitstr l36 1-2; fil hom
displayed only first (1) hit structure per citation

L36 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2002:107321 CAPLUS
TITLE:	Preparation of **imidazolyl derivatives** as agonists or antagonists of somatostatin receptors
INVENTOR(S):	**Thurieau, Christophe** Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis
PATENT ASSIGNEE(S):	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE:	PCT Int. Appl., 369 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010140	A2	20020207	WO 2001-US23959	20010731

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-222584 P 20000801

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Imidazole derivs. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(:Y)NX1X2; C(:Y)X2; C(:NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepd. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addn. of 2-{(1S)-1-amino-2-(indol-3-yl)ethyl}-4-phenyl-1H-imidazole afforded 94% the title compd. V. Compds. I are effective at 0.01-10.0 mg/kg/day.

IT INDEXING IN PROGRESS

IT **252292-69-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

RN 252292-69-6 CAPLUS

CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:795794 CAPLUS

DOCUMENT NUMBER: 132:35701

TITLE: Preparation of **imidazolyl** **derivatives** as as agonists or antagonists of

somatostatin receptors

INVENTOR(S): **Thurieau, Christophe** Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques, S.A., Fr.

SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964401	A2	19991216	WO 1999-US12760	19990608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9944257	A1	19991230	AU 1999-44257	19990608
EP 1086086	A1	20010328	EP 1999-927323	19990608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NO 2000006267	A	20010207	NO 2000-6267	20001211

PRIORITY APPLN. INFO.: US 1998-89087 P 19980612
US 1998-96431 A1 19980612
WO 1999-US12760 W 19990608

OTHER SOURCE(S): MARPAT 132:35701

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(:Y)NX1X2; C(:Y)X2; C(:NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.; m = 0-6] which are useful as agonists or antagonists of somatostatin receptors (no data), and for inhibiting the proliferation of Helicobacter pylori, were prepd. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addn. of 2-{(1S)-1-amino-2-(indol-3-yl)ethyl}-4-phenyl-1H-imidazole afforded 94% the title compd. V. Compds. I are effective at 0.01-10.0 mg/kg/day.

IT **252292-69-6P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazolyl derivs. as as agonists or antagonists of somatostatin receptors)

RN 252292-69-6 CAPLUS

CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



FILE 'HOME' ENTERED AT 15:38:34 ON 27 FEB 2002